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CHAPTER I 
 
INTRODUCTION 
 
γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the 
mammalian central nervous system and is synaptically released by local circuit 
interneurons.  In the adult brain, synaptically released GABA activates ligand-gated 
GABAA receptors to influx chloride ions, hyperpolarize neuronal membranes and thereby 
mediate inhibitory synaptic transmission.  Because normal brain function requires intact 
inhibitory synaptic transmission, interneurons must possess mechanisms to adapt synaptic 
GABA during a wide range of activity states.  I hypothesized that one effective 
mechanism may involve regulating GABA synthesis and vesicular GABA content 
through modulating the supply of glutamine, an indirect GABAergic metabolic precursor, 
by System A glutamine transporters.  In addition, because GABA serves critical roles 
during early hippocampal development, I hypothesized that the role of System A 
transporters at inhibitory synapses also may be developmentlally regulated. Therefore, 
this dissertation explored if modulation of System A surface activity dynamically 
regulated GABA synthesis and inhibitory synaptic transmission in response to changing 
developmental and neuronal activity states. 
 Therefore, in Chapter I, I will begin with a succinct overview of GABA’s 
functional roles in the context of hippocampal maturation and anatomy, followed by 
introducing the primary synaptic event measured in studies presented in Chapters II and 
III.  I will then provide a comprehensive review of the known presynaptic mechanisms 
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that regulate GABA synthesis and vesicular GABA content (the concentration of GABA 
in a synaptic vesicle).  Lastly, I will outline the specific questions driving the hypotheses 
tested in Chapters II and III. 
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Maturation and Anatomy of Hippocampus 
 
The hippocampus is located within the temporal lobe of the cerebral cortex and 
involved in behaviors such as explicit memory, spatial coding and learning as well as in 
neurological disorders such as temporal lobe epilepsy.  Rat hippocampal slices (Figure 1) 
and synaptosomes from multiple postnatal ages (Postnatal (P) day 7-28) were selected as 
the model system utilized for all experiments presented in Chapters II and III.  Therefore, 
in this section, I will first introduce the role for neurotransmitter GABA in hippocampal 
synapse maturation and synaptogenesis.  Lastly, I will outline the anatomy of the 
hippocampus with a focus on neurons located within the CA1 subfield.   
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Figure 1.  Cellular layers within the hippocampus   
A coronal section of rat hippocampus that identifies its multiple cellular layers within the 
CA1 and CA3 subfields.  a, alveus; o, stratum oriens; p, stratum pyramidale; r, stratum 
radiatum; lm, stratum lacunosum-moleculare; m, stratum moleculare; g, granule cell 
layer; h, hilus; l, stratum lucidum.  Image copied from (Freund & Buzsaki 1996). 
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Developmental switch in chloride homeostasis 
 During development, neurons experience a developmental switch in chloride 
homeostasis.  Using intracellular recordings from CA3 pyramidal neurons (the primary 
principal neuron in hippocampus that releases glutamate, the main excitatory 
neurotransmitter) in rat hippocampal slices, Ben-Ari and colleagues identified a form of 
depolarizing neuronal activity termed ‘giant depolarizing potentials’ (GDPs) in only P0-
P8 slices (Ben-Ari et al. 1989).  The exact postnatal day that GDPs disappear depends 
upon the brain region and animal species, yet generally occurs prior to the end of the 
second postnatal week (Ben-Ari et al. 2007).  GDPs provide the primary source of 
neuronal activity during early hippocampal development and are characterized by an 
amplitude of 15-50mV that lasts 300-500ms and a frequency of 0.005-0.2Hz.  Activation 
of GABAA receptors by GABA underlies the GDPs, as bicuculline (10µM), a GABAA 
receptor antagonist, eliminated the depolarizing activity.   
In subsequent studies, a reversal in the usual neuronal chloride gradient was found 
to underlie GABA’s depolarizing activity (Figure 2).  Immature (P0-P7) pyramidal 
neurons express the chloride uptake transporter, NKCC1 (named after its electroneutral 
uptake of 1-Na+, 1K+, 2 Cl- ions) (Marty et al. 2002).  NKCC1 accumulates intracellular 
Cl- ions and generates an outward concentration gradient for chloride efflux upon 
activation of GABAA receptors.  Chloride efflux raises the resting membrane potential to 
chloride’s electrochemical potential (EGABA; a more positive potential due to the outward 
gradient), thereby depolarizing the neuronal membrane.  The magnitude of this 
depolarization is sufficient to remove the voltage-dependent magnesium block from 
NMDA receptors (Leinekugel et al. 1997) and to activate voltage-gated calcium channels 
6 
(Leinekugel et al. 1995).   Consequently, under appropriate conditions, this 
depolarization can trigger action potentials.  Following the first postnatal week, the 
expression pattern of NKCC1 protein shifts from a somatic to a dendritic localization 
(Marty et al. 2002).  During this shift, pyramidal neurons begin expressing KCC2 (a K+, 
2Cl- co-transporter) mRNA at P5, which gradually increases until P15 where adult levels 
are maintained (Rivera et al. 1999).  A similar timeline was identified for KCC2 protein 
expression by hippocampal pyramidal neurons (Lu et al. 1999).  KCC2 effluxes 
intracellular Cl- ions and generates an inward concentration gradient for chloride influx 
upon GABAA receptor activation.  Chloride influx decreases the resting membrane 
potential to EGABA (a more negative potential due to the inward gradient), thereby 
hyperpolarizing the neuronal membrane.  In immature hippocampal neuronal cultures, the 
triggered influx of calcium upon GABAA receptor activation induces transcription of 
KCC2 gene expression, suggesting that GABA itself may mediate the reversal in 
chloride’s concentration gradient (Ganguly et al. 2001).   
 
Synapse maturation and synaptogenesis in hippocampus 
The timeline for neurogenesis and synapse maturation in rat hippocampus is 
sequential.  Genesis of interneurons (Embryonic day 12-13, E12-13) peaks prior to that of 
pyramidal neurons (E16-19) (Danglot et al. 2006) and interneurons receive the first 
synaptic inputs.  At birth (P0), 95% of interneurons (of all cellular layers in area CA1) 
(Hennou et al. 2002) but only 22% of CA1 pyramidal neurons (Tyzio et al. 1999) receive 
synaptic inputs, as determined by recording spontaneous or evoked post-synaptic currents 
(sPSCs or ePSCs respectfully) from each neuron type in P0 rat hippocampal slices.  
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Using this approach, Tyzio and colleagues (1999) identified three populations of CA1 
pyramidal neurons at P0: 1) Synaptically silent neurons that express functional GABAA 
and NMDA receptors; 2) Neurons that only receive GABAergic inputs yet continue to 
express functional NMDA receptors; and 3) Neurons that receive GABAergic and 
glutamatergic inputs.  In this population, sPSCs and ePSCs were partially blocked by 
bicuculline and completely blocked by addition of NMDA and AMPA receptor 
antagonists.  However, in some neurons, sPSCs and ePSCs were mediated only by 
GABAA and NMDA receptors; while the converse, sPSCs and ePSCs mediated only by 
GABAA and AMPA receptors, was never observed.  These findings support that 
GABAergic synapses form prior to glutamatergic synapses.  In addition, active NMDA 
receptor signaling can occur during a period of time when glutamatergic synapses are 
AMPA receptor-silent.  Previous studies have demonstrated that paired presynaptic 
activity with postsynaptic depolarization removes the voltage-dependent magnesium 
block from NMDA receptors, increases influx of extracellular calcium, and thus 
promotes synaptic AMPA receptor expression (Malenka & Nicoll 1997).   
Therefore, Tyzio and colleagues (1999) proposed that in immature neurons, 
GABA’s depolarizing activity provides the postsynaptic depolarization required to 
activate previously silent AMPA synapses.  In 2008, Wang and Kriegstein provided 
further evidence for this hypothesis.  To remove GABA’s “depolarizing activity”, Wang 
and Kriegstein performed in utero electroporation (at E15) of plasmids coexpressing GFP 
and shRNA against NKCC1 (Wang & Kriegstein 2008).  In cortical pyramidal neurons of 
P0 brain slices, knocking-down NKCC1 protein expression shifted EGABA to -70mV, a 
more hyperpolarized potential compared to sham slices (-40mV).  This result implies that 
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activation of GABAA receptors in Nkcc1-shRNA-expressing cells would indeed 
hyperpolarize, not depolarize, the neuronal membrane.  In sham slices, GABAA receptor-
mediated sPSCs were recorded in the first three weeks of postnatal life while AMPA-
receptor-mediated sPSCs remained restricted to the second and third postnatal week.  In 
Nkcc1-shRNA-knockdown cells, the absence of the GABA-induced depolarization 
delayed detecting GABAA receptor-mediated sPSCs until postnatal weeks two and three, 
while AMPA receptor-mediated sPSCs were completely eliminated.  Interestingly, the 
loss of spontaneous AMPA receptor-mediated PSCs could be rescued by 
coelectroporation of two plasmids expressing: 1) Nkcc1-shRNA and 2) a NMDA 
receptor mutant that does not require GABA-induced depolarization for NMDA receptor 
activation.  However, coelectroporation of Nkcc1-shRNA with the wildtype NMDA 
receptor-expressing plasmid rescued the delayed onset of GABAA receptor-mediated 
sPSCs, but not AMPA receptor-mediated sPSCs.  Therefore, GABAergic and 
glutamatergic synapses form via different processes.  These findings also support that 
GABA-induced depolarization is necessary and sufficient to activate previously silent 
AMPA synapses through a NMDA receptor-dependent mechanism (Figure 2).  
GABA’s “depolarizing” activity thereby allows interneurons to provide the source 
and target of the first functional synapses during neuronal maturation.  Therefore, in 
hippocampus, GABA orchestrates inhibitory and excitatory synapse maturation.  This 
role for GABA remains restricted to the first two weeks of postnatal life and thus 
represents one period of the larger developmental window of synaptogenesis (P0-P28).  
Once a sufficient density of glutamatergic synapses form, the reversal in chloride’s 
concentration gradient occurs (by P14), and GABA assumes its role as the primary 
9 
inhibitory neurotransmitter in order to regulate excitatory neurotransmission.  
Synaptogenesis continues to occur, yet the initial population of “unsilenced” AMPA 
synapses now supplies the depolarization required to yield functionally mature 
glutamatergic synapses (Figure 2). 
 For hippocampal interneurons, their morphological features progressively mature 
throughout the period of synaptogenesis.  The dendritic length of interneurons 
progressively increases from P0-P20 where their dendritic arbors adopt morphological 
features at P20 similar to adult interneurons (Lang & Frotscher 1990).  Similarly, 
extension of their axonal arbors gradually increases during the first three postnatal weeks, 
although details are only complete for the subtype of interneurons making axo-somatic 
synapses on pyramidal neurons.  For example, one study calculated the staining density 
for the vesicular inhibitory amino acid transporter (vIAAT or vGAT) from confocal 
images of rat hippocampus in order to mark newly formed GABAergic terminals.  
vIAAT density in stratum pyramidale was increased 6-fold at P21 compared with P7 in 
the CA1 subfield and 4-fold in the CA3 subfield (Marty et al. 2002).  This suggested that 
the majority of axo-somatic synapses on pyramidal neurons are established between P7-
P21.  However, at P0, interneuron synapses on CA1 pyramidal neurons localize to 
stratum radiatum, demonstrating that formation of axo-dendritic synapses likely precedes 
that of axo-somatic synapses (Tyzio et al. 1999).  
The critical role that GABA serves in inhibitory and excitatory synapse 
maturation suggests that the presynaptic metabolic processes that govern the synaptic 
pool of neurotransmitter GABA likely play a critical role in hippocampal maturation.  
Moreover, some of these metabolic processes may be developmentally regulated to 
10 
reflect the changing metabolic demands for GABA as it transitions from an “excitatory” 
to an inhibitory neurotransmitter during postnatal development. 
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Circuitry of Hippocampus  
 Upon maturation, the circuitry of the hippocampus is viewed as a tri-synaptic loop 
containing three main sub-fields: dentate gyrus, area CA3 and area CA1 (Figure 3).  The 
major input and output of the hippocampus is the entorhinal cortex, which is connected to 
other regions within the cerebral cortex.  Afferent axon collaterals from specific layers 
within the entorhinal cortex comprise the perforant path and form excitatory synapses on 
dendrites of granule cells within the stratum moleculare of the dentate gyrus.  Granule 
cells project their axons, mossy fibres, to area CA3, where they form excitatory synapses 
on dendrites of CA3 pyramidal neurons in stratum lucidum.  Axons from CA3 pyramidal 
neurons comprise the schaffer collaterals, which in turn make excitatory synapses on 
dendrites of CA1 pyramidal neurons predominantly in stratum radiatum (str. rad.; but 
also str. oriens) and thus complete the tri-synaptic loop.  Lastly, the primary output of the 
hippocampus consists of axonal projections from CA1 pyramidal neurons that make 
excitatory synapses on neurons of the entorhinal cortex.  
Collectively, five sources (local or extrahippocampal) of glutamatergic afferents 
innervate distinct cellular layers of the hippocampus (left side, Figure 4).  These sources 
include: 1) schaffer-collaterals, 2) entorhinal cortex, 3) thalamus, 4) amygdala, and 5) 
local axon collaterals from CA1 pyramidal neurons (Somogyi & Klausberger 2005).  
Additional inputs include the medial septal area (releasing acetylcholine and GABA) and 
neuromodulatory fibres releasing norepinephrine, serotonin, or dopamine (Freund & 
Buzsaki 1996).  
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Figure 3.  Tri-synaptic circuitry of the hippocampus   
Axonal projections within the Perforant, Mossy fibre, and Schaffer collateral pathways 
comprise the tri-synaptic loop and make excitatory synapses on dendrites of granule cells, 
CA3 and CA1 pyramidal neurons, respectfully.  The entorhinal cortex provides the major 
afferent inputs to the hippocampus and receives the major efferent outputs from CA1 
pyramidal neurons.  Image copied from (Neves et al. 2008). 
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Area CA1 pyramidal neurons and interneurons 
In hippocampus, pyramidal neurons are relatively uniform in appearance while 
interneurons comprise a heterogenous population of multiple subtypes.  Interneurons 
diverge in several features, including their dendritic and axonal projections, neuronal 
firing patterns, and expression of calcium-binding proteins or neuropeptides (Klausberger 
& Somogyi 2008, Somogyi & Klausberger 2005) (Figure 4).  The cell somas of 
pyramidal neurons lie tightly packed within the pyramidal cell layer and exclusively 
receive GABAergic inputs from nearby basket cells (Types 2-4, Figure 4).  Pyramidal 
neurons possess two dendritic trees: 1) Apical dendrites that extend into str. rad. and str. 
lacunosum-moleculare (str. lm.) to receive glutamatergic inputs from schaffer-collaterals, 
the entorhinal cortex, and the thalamus, and 2) Basal dendrites that extend into str. oriens 
to receive glutamatergic inputs from schaffer-collaterals, local CA1 axon collaterals, and 
the amygdala.  The majority of axons from CA1 pyramidal neurons project to the 
entorhinal cortex, but can also extend to the lateral septum, nucleus accumbens, and 
olfactory bulb. 
 The localization of an interneuron’s somatodendritic compartment and axonal 
arbor defines the afferent inputs their dendrites receive and efferent outputs their axons 
target.  For example, basket cells express their cell body near the pyramidal cell layer and 
extend their radial dendrites into str. lm., where they overlay with several distinct 
glutamatergic inputs.  However, their elaborate axonal arbors target the cell body and 
proximal dendrites of CA1 pyramidal neurons, providing exclusive innervations to this 
cellular region.  Oriens-Lacunosum Moleculare (O-LM) cells (Type 7, Figure 4) localize 
their cell body in str. oriens where their horizontal dendrites extend, leaving entorhinal 
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cortical afferents and local CA1 axon collaterals as their main source of glutamatergic 
inputs.  Consistent with their name, O-LM cells project their axons to str. lm., where they 
target distal apical dendrites of CA1 pyramidal neurons.  Interestingly, GABAergic and 
glutamatergic synapses on distal apical dendrites in str. rad. lie in close proximity to one 
another, often without intervening astrocytic processes (Lehre & Danbolt 1998).  This 
unique anatomical arrangement facilitates heterosynaptic cross-talk in area CA1 (see 
‘GABA Synthetic and Metabolic pathways’ section for functional implications). 
Because interneurons fire action potentials and thus release neurotransmitter 
GABA at different times and at targeted regions along CA1 pyramidal dendrites, 
activation of GABAA receptors provides a diverse spatial-temporal control of pyramidal 
neuron excitability.  As previously noted in the adult brain, activation of GABAA 
receptors hyperpolarizes neuronal membranes to shunt excitatory inputs.  For a basket 
cell whose axons solely form perisomatic synapses, this process likely suppresses action 
potential generation.   For O-LM cells that form axo-dendritic synapses, this process 
likely inhibits dendritic calcium-dependent spikes (Miles et al. 1996).  Also, whether the 
interneuron is activated in a feedforward (by the same afferents synapsing on pyramidal 
neurons, e.g. entorhinal cortex) or in a feedback (by activated pyramidal neurons, e.g. 
schaffer-collaterals) manner likely influences the functional consequence of GABAA 
receptor activation (Spruston 2008).  For example, feedforward inhibition shortens the 
temporal window for excitatory synaptic input integration while feedback inhibition 
limits continual action potential firing of CA1 pyramidal neurons.  
An interneuron’s extensive axonal arbor enables it to contact and thus 
synchronize the excitatory output of hundreds of pyramidal neurons.  Hippocampal 
16 
pyramidal neurons process cognitive information by firing at distinct frequencies that 
yield robust oscillatory activity.  These frequencies include theta (4-10 Hz) oscillations 
that occur during exploratory movement, memory tasks, and rapid-eye movement sleep 
and sharp ripple oscillations (120-200 Hz) that occur during slow-wave sleep and 
consummatory behaviors (Klausberger & Somogyi 2008).  Interestingly, interneurons 
that fire during these unique frequencies provide the temporal structure required for this 
oscillatory activity by pyramidal neurons (Klausberger et al. 2003).  For example, basket 
cells that fire rhythmically during theta oscillations entrain and synchronize the 
spontaneous firing of multiple CA1 pyramidal neurons (Cobb et al. 1995).     
Therefore, interneurons play a dynamic role in neuronal network activity.  Their 
divergent morphological features allow each subtype to provide a unique spatio-temporal 
control over pyramidal neuron excitability.  This critical function places further emphasis 
on the necessity to understand the presynaptic mechanisms by which interneurons 
maintain and adapt synaptic GABA during these activity states in both developing and 
mature hippocampus. 
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GABA Receptors and mIPSCs 
  
 The previous section identified the multiple roles that GABA plays during 
hippocampal maturation, including in chloride homeostasis and synapse maturation.  In 
addition, it painted a cellular picture of developing and adult hippocampal neurons, 
specifically of synapses between area CA1 interneurons and pyramidal neurons.  I will 
now zoom-in to this synapse and provide a brief overview of GABA receptors prior to 
introducing the remaining components of the GABA neurotransmitter system.  Lastly, I 
will introduce the main synaptic event elicited by these receptors and measured in studies 
presented in Chapters II and III—miniature Inhibitory Post-Synaptic Currents or mIPSCs 
(Figure 5). 
 
Ionotropic and Metabotropic GABA receptors 
 Neurotransmitter GABA mediates fast inhibitory synaptic transmission through 
phasic activation of postsynaptic ionotropic GABAA receptors.  Upon synaptic release at 
hippocampal inhibitory synapses, GABA molecules reach a peak cleft concentration near 
the millimolar range [500µM, (Jones & Westbrook 1995)].  This high concentration 
enables GABA to synchronously open multiple GABAA receptors clustered on the 
postsynaptic cell.  The time course of the GABA cleft transient is rapid [100-500µs, 
(Farrant & Nusser 2005)], partially due to the binding rate of GABA being slower than its 
diffusion rate (Jones et al. 1998).  Therefore, synaptic activation of GABAA receptors 
likely occurs in nonequilibrium conditions.   
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GABAA receptors are members of the cysteine-loop ligand-gated ion channel 
family and expressed as a heteropentamer that form a chloride and bicarbonate ion-
permeable pore.  Currently 19 mammalian GABAA receptors subunits (α1-6, β1-3, γ1-3, 
δ, ε, θ, π, and ρ1-3) have been cloned, providing a heterogenous and widely diverse array 
of possible GABAA receptor combinations.  However, the predominant stoichiometry 
that mediates phasic inhibition contains 2α-2β-1γ (α1β2/3γ2, α2β2/3γ2, or α3β2/3γ2) with a 
pentamer sequence of γ-β-α-β-α.  In this stoichiometry, the α subunit determines the 
receptor’s affinity for GABA [rank order: α6<α1<α2<α4<α5<<α3 (Bohme et al. 2004)] 
and desensitization and deactivation rates [faster kinetics for α1-containing receptors 
(Farrant & Nusser 2005)].  Moreover, expression of the α-subunit is developmentally 
regulated, with α3 expression decreasing and α1 expression increasing throughout the 
first two weeks of postnatal development (Laurie et al. 1992).  Lastly, GABAA receptor 
trafficking, clustering, stability, and endocytosis are all highly regulated processes that 
contribute to its heterogenous expression and synaptic function (Jacob et al. 2008). 
In addition to phasic activation of synaptic GABAA receptors, GABA also elicits 
tonic activation of extrasynaptic GABAA receptors.  Tonic inhibition is mediated by low 
(nM - µM range), ambient concentrations of GABA that bind high-affinity extrasynaptic 
receptors (generally contain 1δ-2α4/6-2β2/3 subunits) (Glykys & Mody 2007).  Although 
the source of this ambient GABA remains controversial, activation of these extrasynaptic 
receptors provides a tonic input conductance to the postsynaptic cell and may have 
varying effects on neuronal excitability depending upon neighboring synaptic inputs.   
GABA also functions as the primary agonist at both GABAB and GABAC 
receptors.  GABAB receptors are metabotropic receptors coupled to Gi/o-proteins and 
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expressed at both pre- and postsynaptic membranes.  Upon activation, GABAB receptors 
couple their βγ-subunits to potassium channels at postsynaptic membranes to mediate 
membrane hyperpolarization (Bormann 1988) and to calcium channels at presynaptic 
membranes to suppress release of vesicular GABA (Couve et al. 2000).  In addition, 
presynaptic GABAB receptors are functional at birth while postsynaptic receptor function 
is not present until after the first postnatal week (Gaiarsa et al. 1995).  GABAC receptors 
are predominantly expressed in the vertebrate retina and form chloride-permeable ρ-
containing homo- or heteropentamers (Bormann & Feigenspan 1995). 
 
Quantal size and mIPSCs  
 Quantal size is the amplitude of the postsynaptic response to the release of a 
single vesicle filled with neurotransmitter and is measured as the amplitude of a 
miniature postsynaptic current (mPSC; see Figure 4 for recording of mIPSCs).   
Presynaptic and postsynaptic mechanisms exist to control quantal size.  If the 
concentration of transmitter released from a single synaptic vesicle saturates postsynaptic 
receptors, postsynaptic mechanisms (i.e. receptor number, ligand affinity) determine 
quantal size.  If postsynaptic receptors are not saturated, presynaptic mechanisms (i.e. 
amount of transmitter released, vesicular transmitter content) determine quantal size.  
 For interneuron-CA1 pyramidal neuron synapses, synaptic release of a single 
vesicle filled with GABA does not saturate postsynaptic GABAA receptors.   Therefore, 
presynaptic mechanisms that modulate GABA’s concentration in the synaptic cleft 
([GABA]cleft) determine quantal size.  Through whole-cell recordings of mIPSCs from 
CA1 pyramidal neurons in acute hippocampal slices, studies have taken two approaches 
21 
to support this conclusion: 1) the use of allosteric agonists at GABAA receptors and 2) 
direct manipulation of vesicular GABA content.  If the amount of GABA in a single 
vesicle does not saturate GABAA receptors, allosteric agonists that enhance GABA’s 
affinity for its receptor should augment the chloride conductance, and thus increase 
mIPSC amplitudes.  Indeed, Zolpidem (10µm), an allosteric agonist at GABAA receptors, 
increases mIPSC amplitudes (Hajos et al. 2000).  In addition, enhancing GABA synthesis 
and vesicle filling augments vesicular GABA content, increases the synaptic [GABA]cleft 
and thus rapidly increases mIPSC amplitudes (Mathews & Diamond 2003, Hartmann et 
al. 2008).  Consistent with changes in synaptic [GABA]cleft reflecting mIPSC amplitudes, 
reducing vesicular GABA content and thus [GABA]cleft also rapidly decreases mIPSC 
amplitudes (Zhou et al. 2000, Mathews & Diamond 2003).  Therefore, at interneuron-
CA1 pyramidal neuron synapses, vesicular GABA content is bi-directionally regulated 
and is a key determinant of the synaptic [GABA]cleft and quantal size. 
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Figure 5.  Whole-cell patch-clamp recording of mIPSCs from CA1 pyramidal 
neurons 
A step-wise approach to whole-cell recording of mIPSCs from CA1 pyramidal neurons in 
hippocampal slices using the patch-clamp technique.  Upper panel (from left to right), 
Area CA1 is outlined in a cartoon of a hippocampal slice.  The diagram on the right 
illustrates a macroscopic view of a cell-attached patch on the cell soma of a CA1 
pyramidal neuron (green) using a recording electrode.  Interneurons making axo-axonic, 
axo-somatic, and axo-dendritic synapses are labeled purple (top to bottom).  Lower panel 
(from left to right), Upon applying a brief suction within the recording electrode 
(arrows), the cellular membrane is ruptured and the recording electrode now has 
electronic access to the neuron’s intracellular milieu and thus defines the whole-cell 
recording configuration.  Under specific recording conditions, synapses release 
spontaneous, single GABAergic vesicles in an action potential independent manner.  
Upon release of a single vesicle, GABA molecules bind and activate influx (or efflux) of 
chloride ions through ligand-gated GABAA receptors.  Because the neuronal membrane is 
clamped at a constant holding potential (VH = -60mV), the current generated from 
chloride influx at each synapse is integrated at the cell soma and recorded as a mIPSC, 
the final synaptic output.  Scale bar represents 10pA, 20ms. 	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GABA Synthetic and Metabolic Pathways 
 
 In the previous section I described the postsynaptic response by CA1 pyramidal 
neurons upon release of synaptic GABA by interneurons.  Most notably, a single vesicle 
filled with GABA does not saturate postsynaptic GABAA receptors at this synapse.  As a 
result, presynaptic processes that govern the synaptic [GABA]cleft provide one mechanism 
by which interneurons can adapt inhibitory synaptic strength during a range of 
developmental and activity states.  Therefore, in this section, I will provide a 
comprehensive review of GABA synthetic and metabolic pathways at hippocampal 
interneuron terminals in an effort to elucidate these presynaptic processes. 
 
Interneurons require ongoing GABA synthesis 
 In order to maintain synaptic vesicle filling, two primary sources of GABA are 
available for uptake by the vesicular GABA transporter, vGAT: 1) Pre-existing GABA 
available from reuptake by GAT-1, the main neuronal GABA reuptake transporter 
localized at interneuron terminals, and 2) Newly synthesized GABA available from 
decarboxylation of precursor glutamate by glutamic acid decarboxylase (GAD) (Figure 
6).  GAD exists as two isoforms, GAD65 and GAD67.  GAD65 localizes to synaptic 
membranes at inhibitory terminals while GAD67 localization is more diffuse, suggesting 
that GAD65 synthesizes GABA destined for synaptic release (Soghomonian & Martin 
1998). 
Although reuptake transporters are traditionally viewed as the main source that 
supplies neurotransmitter for synaptic vesicle filling, multiple lines of evidence indicate 
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that filling vesicles with GABA does not solely rely on GAT-1 activity.  First, in 
hippocampal (Jensen et al. 2003) or neocortical (Bragina et al. 2008) slices from GAT1 
knock-out mice, neither mIPSC or sIPSC amplitudes are reduced compared to wildtype 
slices.  This suggests that removal of GABA reuptake does not alter vesicular GABA 
content and thereby the size of the postsynaptic response to single or multiquantal 
synaptic events.  Second, the seizure threshold of GAD65 knock-out mice is reduced 
compared to wildtype mice (Kash et al. 1997, Asada et al. 1996).  This finding indicates 
that loss of synaptic GABA synthesis prevents a compensatory increase in inhibitory 
neurotransmission during periods of hyperexcitability.  Lastly, synaptic vesicles 
preferentially package newly synthesized GABA over pre-existing GABA.  In isolated 
GAD65-containing synaptic vesicles, vesicular uptake of [3H]GABA converted from 
substrate [3H]glutamate was actively taken up while uptake of pre-existing [14C]GABA 
was non-existent (Jin et al. 2003).  This preferential uptake of newly synthesized GABA 
is facilitated by GAD65 and vGAT existing as a part of a protein complex on synaptic 
vesicles (Figure 6).  Moreover, this finding demonstrates a functional coupling between 
GABA synthesis and synaptic vesicle filling (Hsu et al. 2000, Jin et al. 2003, Wu et al. 
2007).  Taken together, inhibitory synapses require ongoing GABA synthesis to maintain 
inhibitory neurotransmission. 
Developmental expression patterns of GAT-1 and GAD parallel the timeline for 
synaptogenesis in hippocampus.  Although neurons express GAT-1 protein at birth, its 
uptake activity appears to gain function sometime between P0-P14 (Demarque et al. 
2002).  Positive immunoreactive processes and terminals for GAT-1 gradually increase 
from P10-P30, where an adult-like pattern of expression is adopted at P30.  Interestingly, 
26 
GAT-1 expression on interneuron cell bodies transiently increases between P10-P20, but 
decreases to adult levels by P30 (Yan et al. 1997).  Like GAT-1, GAD protein expression 
is present at birth and the number of GAD-positive neurons amongst all cellular layers 
increases throughout postnatal development and resembles an adult expression pattern by 
P18 (Seress & Ribak 1988).   The correlation between the developmental timeline of 
GAD protein expression with GABA’s developmental roles suggests that the GABA 
synthetic protein machinery may also contribute to inhibitory and excitatory synapse 
maturation. 
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Figure 6.  GABA synthetic and metabolic pathways 
A schematic cartoon illustrates a metabolic coupling between astrocytes (left) and 
inhibitory terminals (right) in order to maintain vesicular GABA synthesis.  Transport 
and enzymatic steps whose contribution to GABA synthesis remains unresolved are 
illustrated in gray.  Two primary sources of GABA are available for vesicular uptake by 
vGAT: 1) Reuptake of pre-existing GABA by GAT-1 and 2) Newly synthesized GABA 
through decarboxylation of glutamate by GAD65.  GAD65 and vGAT are a part of a 
complex of proteins that link GABA synthesis with vesicular filling, and thus vGAT 
preferentially packages newly synthesized GABA over pre-existing GABA.  Neurons 
acquire precursor glutamate primarily through two pathways: 1) Direct uptake of 
synaptically released glutamate by EAAT3 or 2) Uptake of astrocytic glutamine by 
neuronal System A transporters followed by conversion to glutamate either directly 
through the enzyme glutaminase (GLS1) or indirectly through TCA cycle intermediates.  
Astrocytes express glutamine synthetase (GS), which converts glutamate to glutamine, 
providing substrate for efflux by System N transporters and for shuttling back to neurons.  
Astrocytes acquire glutamate through direct uptake by EAAT2 or through multiple 
enzymatic steps from glucose or GABA catabolism. 
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Transmembrane transporters supply GABAergic metabolic precursors 
 In order to maintain ongoing GABA synthesis, inhibitory neurons require a source 
of glutamate, GABA’s immediate metabolic precursor.  One intrinsic source relies on 
neurons synthesizing glutamate de novo from glucose through intermediates of the 
tricarboxylic acid (TCA) cycle.  However, neurons do not express pyruvate carboxylase 
(Yu et al. 1983, Shank et al. 1985), the necessary anaplerotic enzyme required to 
replenish the TCA cycle intermediates depleted to maintain de novo glutamate synthesis.  
Therefore, neurons must acquire a supply of glutamate or metabolic precursors of 
glutamate by transmembrane transporters.  In addition, the coupling of GABA synthesis 
to vesicular GABA filling provides a mechanism whereby supply of these metabolic 
precursors to inhibitory synapses can dynamically regulate vesicular GABA content and 
thus inhibitory neurotransmission. 
 Multiple lines of evidence demonstrate that the Excitatory Amino Acid 
Transporter (EAAT) 3 is one transmembrane transporter that directly supplies inhibitory 
terminals with glutamate for vesicular GABA synthesis (Figure 6).  First, non-pyramidal 
neurons in str. rad. and str. oriens in adult hippocampus express EAAT3 mRNA (Berger 
& Hediger 1998).  EAAT3 immunoreactivity localizes to presynaptic terminals in area 
CA1 of hippocampus (He et al. 2000) and co-localizes with GAD in non-pyramidal 
neurons of cerebral cortex (Conti et al. 1998).  Second, intraventricular infusion of adult 
rats with antisense oligonucleotides to EAAT3 reduces newly synthesized [14C]GABA 
from [14C]glutamate, leading to a reduction in mIPSC amplitudes recorded from 
hippocampal CA1 pyramidal neurons compared to control rats (Sepkuty et al. 2002).  
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These deficits in vesicular GABA synthesis lead to hyperexcitability and development of 
seizures in EAAT3 antisense-treated rats.   
Lastly, our lab has demonstrated that supply of exogenous glutamate (Mathews & 
Diamond 2003) or synaptically released glutamate (Stafford et al. 2009) increases 
vesicular GABA synthesis and thus mIPSC amplitudes in hippocampal slices.  
Interestingly, the mechanism underlying the latter finding required glutamate spillover 
from neighboring glutamatergic synapses.  As a result, spillover only occurred within 
inhibitory terminals that make axo-dendritic synapses on CA1 pyramidal neurons, as 
pyramidal neuron cell bodies are devoid of glutamatergic inputs.  The functional 
consequences of these unique anatomical features within area CA1 are two-fold: 1) 
Astrocytes express EAAT2 which uptakes the majority of synaptically released glutamate 
in order to maintain a low extracellular concentration of glutamate (Danbolt 2001).  
Therefore, EAAT3-mediated glutamate uptake at axo-dendritic inhibitory synapses likely 
constitutes a feedback mechanism to increase inhibitory synaptic transmission only 
during periods of excessive glutamate release and thus “spillover”.  2) The unique spatio-
temporal contribution of this pathway suggests that inhibitory terminals likely rely on an 
additional GABA biosynthetic pathway to support constitutive vesicular GABA 
synthesis. 
 
Astrocytic glutamine contributes to ongoing GABA synthesis 
 In addition to direct glutamate uptake, interneurons can also synthesize glutamate 
from glutamine.  Although interneurons cannot synthesize glutamine, glutamine exists at 
high extracellular concentrations in rat hippocampus (0.2mM) (Lerma et al. 1986) and in 
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human cerebrospinal fluid (0.5-1mM) (McGale et al. 1977).  Therefore in contrast to 
glutamate, glutamine is ubiquitously available to inhibitory synapses for interneuronal 
uptake.  Neurons express phosphate-activated glutaminase type 1 (GLS1) in a cell-type 
dependent manner (Laake et al. 1999), where it localizes to mitochondria and exists in 
both soluble and membrane-bound forms.  GLS1 is an allosteric enzyme regulated by 
multiple cellular signals that include activation by phosphate ions and feedback inhibition 
by glutamate (Kvamme et al. 2001).  GLS1 may synthesize glutamate directly through 
deamidation of glutamine or indirectly through initial conversion of glutamine to TCA 
cycle intermediates (Waagepetersen et al. 1999) (Figure 6).  However, GLS1 expression 
by hippocampal interneurons has not been shown and cortical cultures from GLS1 knock-
out mice reveal impairments in excitatory but not inhibitory synaptic transmission 
(Masson et al. 2006).  In addition, a recent study detected glutaminase enzyme activity 
but not immunoreactivity using current antibodies in cultured astrocytes (Kvamme et al. 
2008).  Therefore, astrocytes and possibly interneurons may express unknown 
glutaminase isozymes that indeed synthesize glutamate from glutamine at inhibitory 
terminals.  Consistent with a role for glutamine in GABA synthesis, modulating 
glutamine levels increase (Battaglioli & Martin 1990, Battaglioli & Martin 1996) or 
decrease (Kapetanovic et al. 1993) newly synthesized GABA levels measured by HPLC 
and GC/MS.   
If glutamine indeed exists as a metabolic precursor of neuronal glutamate and thus 
GABA, what is the source of neuronal glutamine?  Van Den Berg and Garfinkel (1971) 
proposed the first evidence that glutamate and glutamine exist in distinct metabolic 
compartments—astrocytes represent a small compartment that synthesize glutamine and 
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neurons represent a large compartment that utilize glutamine to synthesize glutamate.  
Given that astrocytes selectively express glutamine synthetase (GS) (Norenberg & 
Martinez-Hernandez 1979), which synthesizes glutamine from glutamate, the existence 
of a glutamate-glutamine-GABA (glu-gln-GABA) pathway emerged (Benjamin & 
Quastel 1975).  In this pathway, astrocytes synthesize glutamine from glutamate and 
export glutamine for neuronal uptake, allowing subsequent synthesis of glutamate and 
GABA in inhibitory terminals (Figure 6).  Intrastriatal injections of 10mM MSO, an 
inhibitor of GS, into the neostriatum of adult rats reduced glutamine and subsequently 
GABA levels (Paulsen et al. 1988).  MSO also reduced evoked release of GABA in 
neostriatal tissue slices (Paulsen & Fonnum 1989).   
Despite agreement that astrocytes are the source of neuronal glutamine, the source 
of glutamate to synthesize astrocytic glutamine remains controversial.  One source relies 
on synthesis of glutamate through TCA cycle intermediates supplied by glucose or 
GABA catabolism in astrocytes (Figure 6).  In co-cultures of cerebral cortical neurons 
and astrocytes, 10mM MSO reduced neuronal labeling of GABA from [13C]-acetate 
using [13C]NMR spectroscopy (Sonnewald et al. 1993).  In adult rats, intravenous 
infusion of [13C]-glucose enriched neuronal labeling of glutamine and GABA (Patel et al. 
2001).  Adult astrocytes express both GAT-1 and GAT-3 (Ribak et al. 1996) and GABA 
transaminase (GABA-T) activity (Schousboe et al. 1983).  Upon catabolism of 
synaptically released GABA, GABA-T synthesizes substrates that feed into the TCA 
cycle, yet the functional contribution of this source remains unknown.  In contrast, 
1.4mM MSO in hippocampal slice cultures causes astrocytes to accumulate, but neuronal 
terminals to deplete glutamate, as visualized by immunogold labeling of glutamate using 
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electron microscopy (Laake et al. 1995).  Because astrocytes accumulate glutamate, 
Laake and colleagues concluded that astrocytic uptake of glutamate by EAAT2, not 
glutamate synthesis through the TCA cycle, is the source for synthesis of astrocytic 
glutamine.  Further experiments examining the role of EAAT2 in GABA synthesis will 
be required to distinguish which source of glutamate serves to synthesize glutamine for 
participation in the glu-gln-GABA pathway. 
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System A Sodium-coupled Neutral Amino acid Transporters (SNATs) 
 
 The previous section presented evidence that an EAAT3-independent GABA 
biosynthetic pathway exists and likely involves supply of astrocytic glutamine.  
Therefore, in this section, I will present current evidence supporting and opposing a role 
for neuronal System A Sodium-coupled Neutral Amino Acid Transporters (SNATs) as 
the suppliers of astrocytic glutamine to interneurons.  Also, I will discuss their protein 
expression pattern, their known regulators of transport activity, and their functional 
contributions to both excitatory and inhibitory neurotransmission. 
 
System A transporters as neuronal suppliers of astrocytic glutamine 
 If astrocytes selectively synthesize glutamine, what transmembrane transporter 
supplies interneurons with astrocytic glutamine?  Because glutamine is an essential 
amino acid, it is a substrate for multiple amino acid transporters in the solute carrier 
(SLC) 38 gene family, including Systems A, ASC, L, b0,+, y+L, and N.  Upon functional 
characterization, Systems A, ASC, L and N were found to mediate the majority of 
glutamine transport (Broer & Brookes 2001).  However, the transporter that supplies 
neuronal glutamine for GABA synthesis must meet the following requirements: 1) A 
preference for glutamine transport over other amino acid substrates; 2) Uptake of 
substrate must define the transport mode; and 3) Neurons should predominantly express 
the transporter.   
 Upon cloning and characterizing the properties of individual transporters within 
the above families, one family meeting the above requirements emerged—the System A 
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family of SNATs.  The neuronal System A members include two subtypes, SNAT1 and 
SNAT2.  Hydropathy plots predict that both SNAT1 and SNAT2 possess 11 
transmembrane domains with a cytosolic N-terminus and extracellular C-terminus (Yao 
et al. 2000, Varoqui et al. 2000).  One distinguishing feature of SNAT1 and SNAT2 is 
transport of N-methylated substrates which includes the non-metabolizable glutamine 
analogue, α-(methylamino) isobutyric acid (MeAIB).  MeAIB thereby functions as a 
selective competitive inhibitor for System A transporters.  In heterologous cells that 
express SNAT1 (Varoqui et al. 2000), L-glutamine is the predominant substrate that 
competes with [14C]MeAIB while alanine is the predominant substrate in cells that 
express SNAT2 (Yao et al. 2000).  This is supported by SNAT1 displaying a higher 
affinity for L-glutamine (KM=0.5mM) than SNAT2 (KM=1.7mM).  Furthermore, these 
KM’s for glutamine transport lie within the concentration range for extracellular 
glutamine (0.5-1mM) and therefore suggests that these transporters likely operate near 
saturation. 
 In addition, both SNAT1 and SNAT2 exhibit electrogenic uptake of glutamine.  
In oocytes expressing SNAT1 (Mackenzie et al. 2003) or SNAT2 (Yao et al. 2000), 
[14C]MeAIB uptake is sodium-dependent, as replacing NaCl with choline chloride (ChCl) 
in the extracellular solution abolishes MeAIB uptake.  Sodium binding is voltage-
dependent and precedes amino acid binding in a 1:1 stoichiometry.  The coupling of the 
electrochemical sodium gradient to amino acid transport enables the generation of steep 
concentration gradients across the plasma membrane, allowing uptake to serve as the 
mode of transport for SNAT1 and SNAT2.  Lastly, SNAT1 immunoreactivity does not 
co-localize with GLAST, a marker of astrocytes, in cerebellar granule cell cultures 
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(Varoqui et al. 2000), in hippocampal cultures (Armano et al. 2002), or in hippocampal 
tissue (Mackenzie et al. 2003).  Similar findings are reported for SNAT2 in hippocampal 
cultures (Armano et al. 2002) and primary cortical cultures or hippocampal tissue 
(Jenstad et al. 2009).  Therefore, neurons predominantly express SNAT1 and SNAT2 
(Figure 6).    
Unlike System A, astrocytes that ensheath both excitatory and inhibitory 
terminals selectively express the System N family of SNATs, SNAT3 (Boulland et al. 
2002) and SNAT5 (Cubelos et al. 2005).  System N co-transports glutamine and 1-Na+ in 
exchange for 1-H+.  However, under physiological conditions, SNAT3 transport can 
reverse, allowing efflux of astrocytic glutamine (Chaudhry et al. 1999, Broer et al. 2002).  
This process enables a shuttling of glutamine back to terminals for neuronal uptake 
(Figure 6).    
 
SNAT1 and SNAT2 neuronal expression and cellular localization 
 Although neurons appear to selectively express SNAT1 and SNAT2, their cellular 
localization has called into question their role as suppliers of astrocytic glutamine for 
neurotransmitter GABA synthesis.  Immunohistochemical studies report that both 
glutamatergic and GABAergic neurons express SNAT1 and SNAT2 protein in adult 
thalamus, cerebral cortex, brainstem, striatum, olfactory bulb (Conti & Melone 2006, 
Melone et al. 2004, Melone et al. 2006), cerebellum (Mackenzie et al. 2003, Melone et 
al. 2004, Gonzalez-Gonzalez et al. 2005, Melone et al. 2006), globus pallidus, and 
regions of substantia nigra (Mackenzie et al. 2003).  However, expression could only be 
detected in neuronal cell somas and dendrites.  Likewise, in hippocampus, the majority of 
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SNAT1 and SNAT2 expression was limited to neuronal cell bodies and dendrites, 
although synaptic boutons in cultures positively expressed these transporters (Table 1).  
The absence of strong immunoreactivity of SNAT1 or SNAT2 at synaptic terminals 
suggests that: 1) SNAT1 and SNAT2 contribute to a metabolic pool of GABA that is not 
relevant to its neurotransmitter pool or 2) SNAT1 and SNAT2 participate in the glu-gln-
GABA pathway at synaptic terminals where their protein expression falls below the 
current methodological detection limits.   
Interestingly, recent studies suggest that in hippocampus, glutamatergic neurons 
selectively express SNAT2, as weak staining of non-pyramidal neurons was only 
observed in str. oriens (Table 1).  This finding is in direct contrast to the ubiquitous 
expression on all neurons previously proposed and thus raises an intriguing question:  If 
System A transporters supply astrocytic glutamine for ongoing GABA synthesis, do both 
transporters serve this role or is this role unique to either SNAT1 or SNAT2? 
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SNAT1 and SNAT2 regulation 
 Most of our knowledge regarding the regulation of System A transporters stems 
from studies in non-neuronal systems, leaving a significant deficit in our understanding 
of their unique regulation in neurons.  Early studies in non-neuronal cells and tissues 
demonstrated that growth factors (Ensenat et al. 2001), hypertonicity (Alfieri et al. 2001), 
and insulin (Hyde et al. 2002) stimulate SNAT2-mediated uptake of various amino acids.  
The mechanism required either de novo synthesis of SNAT2 protein (Ensenat et al. 2001, 
Alfieri et al. 2001) or insertion of existing transporters at the cell surface (Hyde et al. 
2002).  In neocortical neuronal cultures, chronic deprivation (8h) of amino acids 
increases SNAT2, but not SNAT1, uptake activity due to increased de novo synthesis of 
SNAT2 protein (Grewal et al. 2009).  In the same system, a one-hour treatment with 
brain-derived neurotrophic factor (BDNF) stimulates SNAT1 activity by increasing 
mRNA and protein expression (Burkhalter et al. 2007).  Interestingly, shortening the 
BDNF incubation to twenty minutes stimulates SNAT1 uptake activity without 
enhancing protein expression, suggesting a possible translocation of SNAT1 from an 
intracellular compartment to the cell surface.  The previous two studies demonstrate that 
neurons can uniquely regulate SNAT1 and SNAT2 uptake activity in order to meet 
specific metabolic demands.  In addition, both SNAT1 and SNAT2 are negatively 
regulated by protons (Chaudhry et al. 2002) and possess sites for posttranslational 
modifications, including three PKC consensus sequences (N-terminus and an intracellular 
loop) and two extracellular glycosylation sites (Mackenzie & Erickson 2004).  However, 
whether these posttranslational modifications regulate System A transport activity 
remains unknown. 
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SNAT1 and SNAT2 function in excitatory synaptic transmission 
 Given that both glutamatergic and GABAergic neurons require a supply of 
glutamate to maintain their neurotransmitter pools, one might expect that SNAT1 and 
SNAT2 also supply astrocytic glutamine for neurotransmitter glutamate synthesis.  
Alternatively, given that glutamatergic neurons appear to selectively express SNAT2 in 
hippocampus (Jenstad et al. 2009, Gonzalez-Gonzalez et al. 2005), SNAT1 and SNAT2 
may play unique roles in the synthesis of neurotransmitters GABA and glutamate.  
Although future chapters will focus on the role of System A transporters in modulating 
inhibitory neurotransmission, I will provide a brief background of their controversial role 
in excitatory neurotransmission in order to provide context for future points of 
discussion.  
 Several studies have examined if glutamine supplied by System A transporters 
contributes to neurotransmitter glutamate synthesis and synaptic release.  In acute rat 
hippocampal slices (P12-24), L-glutamine (4mM) increased the concentration of 
glutamate in the synaptic cleft and thus mEPSC amplitudes recorded from CA1 
pyramidal neurons.  However, this increase only occurred at glutamine incubation times 
greater than 4 hours (Kam & Nicoll 2007).  Glutamine supplied by System A transporters 
mediated the delayed effect, as MeAIB (25mM) in the presence of L-glutamine (4mM) 
prevented the increase in mEPSC amplitude.  This timecourse suggests that glutamine 
does not contribute to ongoing glutamate synthesis and maintenance of acute excitatory 
neurotransmission. 
 However, recent studies demonstrate that glutamatergic neurons require 
glutamine to sustain the excessive excitability in various in vitro models of seizure-like 
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activity.  In horizontal thalamic slices from juvenile rats (Bryant et al. 2009) or in 
hippocampal slices from adult rats (Bacci et al. 2002), blockade of postsynaptic GABAA 
receptors induces spontaneous epileptiform oscillations (bursts of action potentials at 
defined frequencies) mediated by initial activation of ionotropic glutamate receptors.  
Sustaining this hyperexcitability required glutamine, as MeAIB (5-12.5mM) reduced 
either the duration (Bryant et al. 2009) or frequency (Bacci et al. 2002) of these 
epileptiform oscillations.  Similarly, in neocortical slices, 10mM MeAIB blocked the 
polyphasic activity of evoked field potentials that characterizes the hyperexcitability 
observed in the neocortical undercut model of epilepsy (Tani et al. 2007).  Tani and 
colleagues concluded that cortical excitatory neurons increase protein expression of both 
SNAT1 and SNAT2 to mediate the increased glutamine requirement, although only the 
amount of SNAT2 protein appears increased in immunoblots. 
 Taken together, it appears that glutamatergic neurons may only require glutamine 
to synthesize glutamate under pathological conditions of increased metabolic demand.  In 
addition, SNAT2 may play a unique role as the main System A transporter on 
glutamatergic neurons mediating this requirement. 
 
SNAT1 and SNAT2 function in inhibitory synaptic transmission 
 Similar to the immunohistochemical data, results from several studies indicate 
that the functional role of System A transporters in the glu-gln-GABA pathway remains 
controversial.  First, in adult guinea pig cortical slices under depolarizing conditions 
(40mM KCl), 10mM Histidine, but not 10mM MeAIB, inhibits the labeling of glutamate, 
glutamine, and GABA from [13C]-glucose measured using NMR spectroscopy (Rae et al. 
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2003).  The authors conclude that during prolonged periods of synaptic activity, 
astrocytic glutamine contributes to synaptic GABA through uptake by a non-System A 
glutamine transporter that remains sensitive to histidine.  However, this study does not 
eliminate the possibility that glutamine synthesized from uptake of synaptically released 
glutamate by EAAT2 on astrocytes (v. de novo synthesis of glutamate from glucose) is 
shuttled to inhibitory synapses for uptake by System A transporters.   
 Second, in adult rat hippocampal slices, 5mM MeAIB did not reduce mIPSC 
amplitudes in the absence of synaptic activity, suggesting that glutamine does not 
maintain basal GABA synthesis.  However, applying a moderate burst stimulation 
protocol (4 pulses of 50Hz, repeated every 20s for 15m) beneath (20-50µm) the CA1 
pyramidal layer in stratum rad. acutely increased evoked IPSC (eIPSC) amplitudes 
recorded from CA1 pyramidal neurons (Liang et al. 2006).  This increase required 
astrocytic glutamine, as both 5mM MeAIB and 1.5mM MSO independently reduced 
post-stimulation eIPSC amplitudes below pre-stimulation amplitudes.  The authors 
conclude that this stimulation increased flux of glutamine through the glu-gln-GABA 
pathway, but they did not explore whether the entire cycle or individual processes within 
the pathway were upregulated to mediate the mechanism.  They do demonstrate that the 
increase in control eIPSC amplitudes was partly mediated by increasing the release 
probability of GABAergic vesicles, but this increase was sustained in the presence of 
both MeAIB and MSO.   
 Lastly, applying a high frequency stimulation (HFS) protocol (100Hz for 1s) 
again beneath the CA1 pyramidal layer in str. rad. of adult mouse hippocampal slices 
acutely increased mIPSC amplitudes recorded from CA1 pyramidal neurons (Hartmann 
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et al. 2008).  In contrast to the previous study, this increase did not require glutamine, as 
5mM MeAIB did not reduce the stimulated increase in mIPSC amplitudes.  Instead, 
pharmacological blockade of glutamate uptake combined with GABA reuptake by GAT-
1 eliminated the stimulated increase.  The authors concluded that HFS enhanced the 
release of neurotransmitter glutamate and GABA available for uptake at inhibitory 
terminals (and presumably vesicular GABA content) although the authors did not provide 
any data to support this mechanism.  In addition, electrical stimulation in str. rad. 
probably stimulated only a subpopulation of interneuron terminals, while multiple 
populations of interneurons likely contributed to the population of mIPSCs recorded.  
Therefore, the hypothesized mechanism above may not accurately reflect the cellular 
processes that mediate the increase in synaptic GABA at the subpopulation of stimulated 
interneuron terminals.  Taken together, glutamine’s contribution to activity-dependent 
GABA synthesis remains controversial and possibly reflects the different approaches 
applied to increase neuronal activity.    
In summary, whether System A transporters supply glutamine to maintain 
ongoing GABA synthesis constitutively or in an activity-dependent manner remains 
unresolved.  However, because glutamine exists at high extracellular concentrations that 
are ubiquitously available to interneuron terminals, constitutive glutamine uptake is a 
likely mechanism by which the majority of interneurons can maintain ongoing GABA 
synthesis.  Furthermore, if System A transporters operate at saturation as biochemical 
studies suggest, up-regulating the surface activity of System A transporters may be an 
effective mechanism to increase neuronal glutamine supply and thus enhance GABA 
synthesis during periods of increased neuronal demand. 
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Plasticity at Hippocampal Inhibitory Synapses 
 
The previous section outlined the controversial role for System A transporters as 
neuronal suppliers of astrocytic glutamine for GABA synthesis.  It also demonstrated our 
lack of understanding of System A transport function and regulation on interneurons.  
Regardless, in order for modulation of System A transport activity to dynamically 
regulate GABA synthesis and vesicular GABA content, inhibitory synapses must exhibit 
plastic properties.  Synaptic plasticity represents the process by which different stimuli or 
cellular signals modify the structure or function of synapses.  Long-Term Potentiation 
(LTP) and Long-Term Depression (LTD) increase and decrease synaptic strength, 
respectively, and thus represent one model of synaptic plasticity.  In addition, synapses 
possess short-term mechanisms of synaptic plasticity that allow neurons to acutely adapt 
to a range of activity states.  Like excitatory synapses, inhibitory synapses appear to be 
remarkably plastic.  In this brief section, I will provide examples of LTPGABA and 
LTDGABA at both developing and mature inhibitory synapses to illustrate this point. 
 
Plasticity at interneuron synapses on CA1 pyramidal neurons 
 Within a restricted time window during hippocampal maturation (P0-P8), 
delivering “depolarizing pulses” [DPs; 20 pulses (500ms each, -80/-90 to 0mV step) at 
0.1Hz] to CA3 pyramidal neurons induced a long-lasting (>30m) increase in spontaneous 
GABAA receptor-mediated post-synaptic current (sGABAA-PSC) amplitudes and 
frequency (Gubellini et al. 2001).  In addition, DPs enhanced miniature GABAA-PSC 
frequency but not amplitude, suggesting that DPs increase the probability of GABAergic 
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vesicle release at individual inhibitory terminals.  This enhanced release of synaptic 
GABA activates GABAA receptors to efflux chloride, depolarize the postsynaptic 
membrane and activate voltage-gated calcium channels.  This process triggers calcium 
influx, a requirement for this form of LTPGABA (Caillard et al. 1999).  LTPGABA induction 
also requires activation of presynaptic Tropomyosin-related kinase receptor B (TrKB) 
through its endogenous ligands, BDNF or neurotrophin-4 (Gubellini et al. 2005).  The 
authors propose that the triggered calcium influx from GABAA receptor activation likely 
stimulates endogenous BDNF release, which in turn activates presynaptic TrkB receptors 
at interneuron terminals to increase synaptic release of GABA.  This example of 
LTPGABA expressed at immature inhibitory synapses presents one possible activity-
dependent mechanism by which GABA facilitates synaptogenesis and hippocampal 
maturation.   
In adult hippocampal slices, afferent fibres within str. rad. stimulated at theta-
burst (5 bursts of 4 stimuli at 100Hz, 200ms apart) frequencies induced a long-lasting 
increase in evoked IPSC (eIPSC) amplitudes recorded from CA1 pyramidal neurons 
(Patenaude et al. 2003).  LTPGABA was not associated with a change in the paired-pulse 
ratio, consistent with a postsynaptic locus of expression that does not involve changes in 
GABA release.  Blockade of GABAB or group I/II mGluRs each partially reduced 
LTPGABA, while introducing the calcium chelator BAPTA into the recording pipette 
completely blocked LTPGABA.  These findings suggested that induction of LTPGABA 
involved calcium influx postsynaptically, although the precise molecular signals were not 
explored.    
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Adult interneuron-CA1 pyramidal neurons synapses are also capable of eliciting 
long-term depression (LTDGABA) through a heterosynaptic mechanism involving 
neighboring glutamatergic terminals.  High frequency (2 trains of 100 stimuli at 100Hz, 
20s apart) or theta-burst (10 bursts of 5 stimuli at 100Hz, 200ms apart) stimulation of 
afferent fibres within str. rad. induced a long-lasting reduction in eIPSC amplitudes 
recorded from CA1 pyramidal neurons (Chevaleyre & Castillo 2003).  LTDGABA was 
associated with an increase in the paired-pulse ratio after HFS and thus consistent with a 
presynaptic reduction in evoked GABA release.  Interestingly, stimulating afferent fibres 
within the str. pyramidale layer failed to induce LTDGABA, consistent with a 
heterosynaptic mechanism between glutamatergic and GABAergic neurons that form 
synapses on distal CA1 apical dendrites.  Subsequent pharmacological experiments 
revealed that synaptically released glutamate activates postsynaptic group I mGluRs to 
increase downstream diacylglycerol and consequently 2-AG production.  2-AG functions 
as a retrograde signal, where it transverses the plasma membrane and synaptic cleft to 
activate presynaptic endocannabinoid receptors (CB1) expressed at interneuron terminals.  
Activation of CB1 receptors can then decrease GABA release short-term through 
inhibition of voltage-gated calcium channels or long-term through reduced PKA-
mediated signaling involving the active zone protein RIM1α (Chevaleyre et al. 2007). 
 
Plasticity at glutamatergic synapses on interneurons 
 Multiple studies have identified mechanisms of long-term plasticity at 
glutamatergic synapses on area CA1 interneurons that involve both NMDA receptor-
dependent and -independent mechanisms (Kullmann & Lamsa 2007).  In P21-P28 
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hippocampal slices, paired stimulation of schaffer-collaterals (2Hz for 1m) with post-
synaptic depolarization of str. rad. interneurons resulted in a NMDA receptor-dependent 
potentiation of the EPSP initial slope (a hallmark of LTP) (Lamsa et al. 2005).  LTPGABA 
occurred in a small proportion interneurons that participate in feedforward inhibition and 
thus may serve as a mechanism to counterbalance excessive excitability at schaffer 
collateral-CA1 pyramidal neuron synapses.  Conversely, HFS (5 pulses at 100Hz, 
repeated 20 times) of local CA1 axon collaterals paired with post-synaptic 
hyperpolarization of str. oriens interneurons resulted in LTPGABA that required calcium-
permeable AMPA receptor activation (Lamsa et al. 2007).  This form of LTPGABA 
occurred robustly in interneurons that participate in feedback inhibition and thus may 
limit CA1 pyramidal firing. 
 LTP and LTD define traditional mechanisms of synaptic plasticity that alter 
presynaptic vesicle release probability or postsynaptic receptor responsiveness.  
Alternatively, presynaptic control of quantal size has gained recent attention as an 
additional mechanism of synaptic plasticity (Edwards 2007), yet mechanisms that 
underlie this form of synaptic plasticity at hippocampal interneuron terminals remain 
unresolved.   
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Section Summary, Hypotheses and Central Questions 
 
 In hippocampus, GABA serves multiple roles during development and throughout 
adulthood, which include: 1) orchestrate synapse maturation and synaptogenesis, 2) 
maintain inhibitory synaptic transmission, and 3) regulate the excitability and 
synchronize the neuronal output of principal neurons.  The previous section demonstrated 
that inhibitory synapses are indeed plastic, yet we know very little about presynaptic 
mechanisms that adapt GABA levels during the wide range of developmental and activity 
states an interneuron experiences.  In addition, it is now apparent that a functional 
coupling exists between GABA synthesis and vesicle filling and that neurons require a 
supply of precursor glutamate to maintain GABA synthesis and vesicle content.  
Therefore, transmembrane transporters that supply glutamate, or glutamine, provide an 
effective presynaptic mechanism to maintain or adapt GABA levels in an activity-
dependent manner.  However, the hippocampus’ unique anatomical features likely 
prevent direct glutamate uptake by EAAT3 to maintain constitutive GABA synthesis, and 
moreover, may only provide an adaptive mechanism to augment GABA synthesis at a 
sub-population of inhibitory terminals.   
Because glutamine is ubiquitously available to inhibitory terminals, I hypothesize 
that glutamine uptake by SNAT1 and/or SNAT2, with its subsequent conversion to 
glutamate and GABA, defines an additional, independent pathway to maintain 
constitutive GABA synthesis.  Since System A transporters likely operate near saturation, 
I also hypothesize that up-regulation of System A surface activity provides interneurons 
with an effect presynaptic mechanism to augment GABA synthesis, vesicular GABA 
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content, and inhibitory synaptic strength in response to increased neuronal demand.  
Lastly, because GABA’s role changes throughout postnatal development, I hypothesize 
that the potential constitutive or activity-dependent roles of System A transporters may be 
developmentally regulated to link the activity-related demands of GABA to its rate of 
synthesis. The questions asked in Chapters II and III that drove the above hypotheses are 
as follows: 
 
In Chapter II, I asked the following questions: Do System A transporters 
constitutively supply inhibitory terminals with glutamine to maintain ongoing GABA 
synthesis and inhibitory synaptic transmission?  If so, does this supply of glutamine exist 
in a dynamic equilibrium with GABA synthesis and vesicle filling, similar to glutamate 
supplied by EAAT3?  Moreover, what are the cellular processes upstream of System A 
transporters that supply glutamine to inhibitory terminals?   
 
 In Chapter III, I asked two central questions: 1) Does neuronal activity upregulate 
the surface activity of System A transporters in order to increase glutamine supply, 
vesicular GABA synthesis and inhibitory synaptic transmission during periods of 
increased metabolic demand? and 2) Are either the potential constitutive or activity-
dependent contributions of System A-mediated glutamine uptake to synaptic GABA 
developmentally regulated?  If so, what is the mechanism and does it uniquely involve 
one System A subtype (SNAT1 or SNAT2)?   
 
 
50 
CHAPTER II 
 
GLUTAMINE UPTAKE BY SYSTEM A TRANSPORTERS 
MAINTAINS NEUROTRANSMITTER GABA SYNTHESIS AND  
INHIBITORY SYNAPTIC TRANSMISSION 
 
Introduction 
 
To maintain inhibitory neurotransmission in the brain, GABA must be supplied to 
recycling synaptic vesicles.  Inhibitory neurons express GABA transporters, but there is 
no evidence that reuptake of transmitter is required to maintain the synaptic pool of 
GABA.  Alternatively, inhibitory neurons are capable of GABA synthesis from glutamate 
using glutamic acid decarboxylase (GAD).  They must, however, have a supply of 
glutamate because neurons are not capable of ongoing glutamate production (Bak et al. 
2006).  The high affinity sodium-dependent glutamate transporter EAAT3 is expressed 
by interneurons of the hippocampus (Berger & Hediger 1998, Kugler & Schmitt 1999) 
and is observed on inhibitory synaptic terminals (He et al. 2000, Rothstein et al. 1994).  
Knockdown of EAAT3 in vivo reduces GABA synthesis and results in spontaneous 
epileptic seizures (Sepkuty et al. 2002).  Electrophysiological studies show that the 
vesicular content of GABA is rapidly altered in response to changes in glutamate uptake 
(Mathews & Diamond 2003), demonstrating that glutamate supply to neurons regulates 
neurotransmitter GABA synthesis, which in turn regulates vesicular filling and synaptic 
strength. 
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Biochemical studies (Paulsen et al. 1988, Battaglioli & Martin 1991, Sonnewald 
et al. 1993, Battaglioli & Martin 1996, Waagepetersen et al. 1999, Rae et al. 2003) 
indicate that glutamine also may contribute to neurotransmitter GABA synthesis.  When 
examined in hippocampal slices, exogenously applied glutamine does not enhance 
GABA release (Szerb & O'Regan 1984), but endogenous glutamine content of slices 
decreases over time and this decline is followed by a slow (over 3 to 6 hours) reduction in 
GABA levels (Kapetanovic et al. 1993).  Although there are several transporters that are 
capable of mediating uptake of glutamine by neurons, SNAT1 and SNAT2, comprising 
the System A subfamily of sodium-coupled neutral amino acid transporters, appear to be 
the most important. They are expressed in excitatory and inhibitory neurons (Reimer et 
al. 2000, Mackenzie et al. 2003, Melone et al. 2004, Melone et al. 2006), are observed at 
synaptic contacts in hippocampal neurons in culture (Armano et al. 2002) and therefore 
have been suggested to supply substrate for neurotransmitter synthesis.  Once taken up, 
glutamine conversion to glutamate is thought to be catalyzed by phosphate-activated 
glutaminase type 1 (GLS1) (Kvamme & Olsen 1980).  However, GLS1 expression in 
GABAergic neurons has not been shown, and knockout of this gene in mice impaired 
glutamatergic but not GABAergic synaptic transmission (Masson et al. 2006).  Moreover, 
recent biochemical and immunohistochemical studies have argued against a role for 
System A transporters in neurotransmitter metabolism (Rae et al. 2003, Melone et al. 
2004, Conti & Melone 2006).  In one study, glutamine uptake was shown to augment 
inhibitory synaptic transmission under certain stimulation protocols (Liang et al. 2006), 
suggesting that the glutamine supply may be required for GABA synthesis only when 
demand reaches a critical level. 
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Glutamate released from excitatory synapses is normally taken up by astrocytes 
that express high levels of glutamate transporters, primarily EAAT2, and is subsequently 
converted to glutamine by glutamine synthetase (GS) (Martinez-Hernandez et al. 1977).  
Astrocytes express the System N glutamine transporters, SNAT3 and SNAT5, which 
have been proposed to transfer glutamine back to neurons by reverse transport (Chaudhry 
et al. 1999, Broer & Brookes 2001, Cubelos et al. 2005).  Since neuronal glutamate 
transporters regulate the synaptic pool of GABA in hippocampal interneurons (Mathews 
& Diamond 2003), we sought to determine the role of System A glutamine transporters in 
the synthesis of GABA at inhibitory synapses.  Our results demonstrate that glutamine 
transporters on inhibitory neurons of the hippocampus contribute to the supply of 
glutamate required for GABA synthesis.   IPSC and mIPSC amplitudes were rapidly 
reduced in response to interrupting the glutamine supply from astrocytes, consistent with 
a reduction in the GABA content of synaptic vesicles.  Our data demonstrate that a 
constitutive supply of glutamine from astrocytes is necessary to maintain inhibitory 
synaptic transmission even under resting conditions. 
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Experimental Procedures 
 
Materials 
MeAIB, DL-threo-b-hydroxyaspartic acid (THA), L-histidine, L-methionine 
sulfoximine (MSO), 6,7-dinitroquinoxaline-2,3-dione (DNQX) and dizocilpine maleate 
(MK-801) were obtained from Sigma (St. Louis, Missouri, USA).  Dihydrokainate 
(DHK) and TTX were obtained from Tocris (Ellisville, Missouri, USA). 
 
Preparation of hippocampal slices and electrophysiological recording 
Seven to fourteen day old Sprague Dawley rats were deeply anesthetized with 
isoflurane and decapitated under a protocol approved by Vanderbilt University’s 
Institutional Animal Care and Use Committee.  Hippocampi were removed and cut into 
400 µm sections (Vibratome Company, St. Louis, MO) in an ice-cold oxygenated 
solution containing (in mM): sucrose 75, NaCl 87, KCl 2.5, MgCl2 7, CaCl2 0.5, 
NaH2PO4 1.25, glucose 25, and NaHCO3 25.  Slices were transferred to a chamber 
containing artificial cerebrospinal fluid (ACSF), which contained (in mM): NaCl 119, 
CaCl2 2.5, KCl 2.5 MgCl2 1.3, Na2PO4 1, NaHCO3 26.2 and glucose 11, (pH 7.4, 290 
mOsm) and bubbled with 95% O2/5% CO2.  Slices were incubated at 35oC for 30 
minutes, then at room temperature for 30 minutes before recording. 
Patch pipettes with resistances of 3-5 MΩ  were filled with a solution containing 
(in mM): cesium chloride 130, HEPES 10, EGTA 10, lidocaine N-ethyl bromide (QX-
314) 1, Na2+-ATP 0.2, and Mg2+-ATP 2 (pH 7.4, 290 mOsm).  Whole cell recordings 
were obtained at a holding potential of –60 mV with a MultiClamp 700A amplifier 
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(Molecular Devices Corporation, Sunnyvale, CA).  Access resistance was monitored 
throughout the experiment and data were discarded if increase was more than 20%.  
Slices were constantly perfused at approximately 2 mL/min with ACSF (bubbled with 
95% O2/5% CO2) containing DNQX (10 µM) and MK-801 (5 µM) to block postsynaptic 
glutamate receptors.  After control currents were obtained, a five-minute period of 
perfusion with drug occurred before the drug effect was evaluated.  Previous studies have 
shown that the effects of transporter (Mathews & Diamond 2003) and enzyme (Cavelier 
& Attwell 2005) inhibitors on neurotransmitter metabolism occur within five minutes.  
Recovery of responses similarly was assessed after a five-minute washout period.  IPSCs 
were evoked with a bipolar stainless steel electrode placed in stratum oriens (constant 
current stimulation, 25-100 mA, 100 ms duration).  For experiments evaluating the effect 
of MeAIB on post-synaptic GABA receptors, GABA (10 mM) was pressure-applied from 
a glass pipette in ACSF alone and during perfusion of the slice with 10 mM MeAIB.  
Spontaneous miniature IPSCs (mIPSCs) were obtained in the presence of 0.5µM 
tetrodotoxin (TTX).  For “evoked” mIPSC experiments, hyperosmolar sucrose (500 mM 
in ACSF containing TTX, DNQX and MK-801) was pressure applied for 3 seconds at 
two-minute intervals with a glass pipette near the neuron soma. All experiments were 
performed at room temperature unless otherwise indicated.  
 
Data analysis 
For IPSC analysis, 15 responses were averaged in each condition to determine the 
peak current, and the drug effect in multiple cells was assessed using the paired t-test.  
For mIPSC analysis, individual events meeting threshold criteria were detected using 
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MiniAnalysis software (Synaptosoft, Fort Lee, NJ, USA) and visually inspected to 
exclude artifacts.  Those single events arising from a stable baseline were used for 
analysis.  At least 100 events were recorded from each cell in each condition, and the 
median was calculated.   Each experiment was performed in multiple cells (‘n’; range 5-
9) prepared from at least 3 animals and the mean of the medians ± standard deviation was 
reported for each condition.  To assess the drug effects, changes in median amplitudes 
during drug application were reported as a percent change from baseline ± SEM.  Data 
were tested for normality (Kolmogorov-Smirnov test) and, unless otherwise noted, passed 
the normality test and were compared using a paired t-test.  Cumulative probability 
histograms were generated by averaging (from multiple cells) the distribution of mIPSC 
amplitudes, normalized to the mean control mIPSC amplitude for each cell.   For repeated 
measures of mIPSC amplitudes in different conditions (i.e. experiments depicted in figure 
6), one-way repeated measures ANOVA was used. 
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Results 
 
To determine the role of glutamine uptake by neurons in the synthesis of GABA 
destined for synaptic release, we examined the effect of α-(methyl-amino) isobutyric acid 
(MeAIB), a selective system A transport inhibitor (Broer & Brookes 2001), on IPSCs 
recorded from CA1 pyramidal neurons in hippocampal slices.  With an apparent affinity 
of 1.1 mM (Mackenzie et al. 2003), MeAIB has been used at 5-50 mM to inhibit System 
A transporters in a variety of in vitro studies (Bacci et al. 2002, Rae et al. 2003, Liang et 
al. 2006).  MeAIB (10 mM) reduced electrically evoked IPSCs by 37 ± 9 % of control 
(p<0.001, n=13 cells; Figure 7A) without significantly changing the paired-pulse ratio 
(PPR was 110 ± 5 % of control; p=0.09; Figure 7B,C), consistent either with a reduction 
in [GABA] in the synaptic cleft without a change in release probability, or with a post-
synaptic effect on GABAA receptors.  To address the latter possibility, we tested the 
effect of MeAIB (10 mM) on the response to pressure-applied GABA.  MeAIB did not 
alter the peak current elicited by GABA (10 mM) on CA1 pyramidal neurons (current in 
MeAIB was 97 ± 2 % of control; n=3; Figure 7D), demonstrating that MeAIB did not 
affect GABAA receptors at this concentration. 
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Figure 7.  MeAIB reduces electrically-evoked IPSCs without altering paired-pulse 
ratio or blocking postsynaptic GABAA receptors 
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Figure 7.  MeAIB reduces electrically-evoked IPSCs without altering paired pulse 
ratio or blocking post-synaptic GABAA receptors 
A, Electrically evoked IPSC in control solution (black) and in the presence of the SNAT1 
inhibitor, MeAIB (10 mM, gray).  B, IPSCs evoked by a pair of stimuli 50 ms apart in 
control solution (black) and in 10 mM MeAIB (gray).  Scale bars in A and B represent 
100 pA and 25 ms.  C, Comparison of the paired pulse ratio (IPSC2/IPSC1) in control 
(black) and MeAIB (gray).  Error bars indicate SEM.  D, Representative currents elicited 
by application of GABA (10 mM) in control (black) and in the presence of MeAIB (10 
mM, gray).  Bar beneath traces indicates duration of GABA application.  Scale bars 
represent 500 pA and 200 ms. Graph represents mean response ± SEM in the presence of 
MeAIB as a percent of control response. 
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To investigate the alternative that MeAIB reduced GABA release, we examined 
its effect on responses to the release of single vesicles.  Median miniature IPSCs 
(mIPSCs) amplitudes were reduced by 16 ± 5% (from 32.7 ± 8.2 pA to 27.3 ± 8.0 pA: p 
= 0.01, n = 8 cells; Figure 8A-C) after 5 minutes of perfusion with MeAIB.  When 
examined, the change was reversible after drug washout (median amplitude in recovery 
compared with MeAIB; p=0.005; n=4 cells; see Figure 8B).  The frequency of mIPSCs 
was unchanged; the median inter-event interval was 1.2 ± 0.9 s in control and 1.5 ± 1.0 s 
in MeAIB (p=0.15, Wilcoxon Signed Rank test, n = 9 cells; Figure 8D).  Together with 
its lack of effect on paired pulse ratio, these data showing that MeAIB alters both IPSC 
and mIPSC amplitudes without altering the probability of vesicle release are consistent 
with a reduction in vesicular content of GABA. 
Because the activity of transporters and enzymes are highly sensitive to 
temperature, we examined the effect of MeAIB at 34°C and found no difference in the 
effect of MeAIB on mIPSC amplitudes compared with room temperature.  Median 
mIPSC amplitudes were reversibly reduced 15 ± 4 % (from 36.1 ± 7.6  pA to 30.4 ± 5.8 
pA:  p = 0.005,  n = 9 cells; recovery compared with MeAIB: p=0.03, n = 8; Figure 
9A,C).  Additionally, because non-specific effects of drugs may occur at high 
concentrations, we evaluated the effect of histidine, a non-selective inhibitor of both 
System A and System N transporters (Broer & Brookes 2001).  Similar to MeAIB, 
histidine (10 mM) reduced median mIPSC amplitudes by 21 ± 5 % (from 34.5 ± 6.8  pA 
to 27.1 ± 6.0 pA: p = 0.02, n = 6 cells; Figure 9B,C). 
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Figure 8.  MeAIB reduces mIPSC amplitudes but does not alter frequency 
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Figure 8.  MeAIB reduces mIPSC amplitudes but does not alter frequency 
A, Sample current traces showing continuous recordings in control solution (black) and 
after 5 minutes in 10 mM MeAIB (gray).  Scale bars represent 25 pA and 25 ms. B, 
Average mIPSC waveforms from a representative cell in control, MeAIB and after drug 
washout.  Scale bars represent 10 pA and 20 ms.  C, Cumulative probability histograms 
of normalized mIPSC amplitudes in control solution (black symbols) and in the presence 
of MeAIB (gray symbols). Data were averaged from 8 cells and error bars indicate SEM.  
D, Comparison of median inter-event interval in control (black symbols) and MeAIB 
(gray symbols).  Error bars indicate SD. 
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Figure 9.  Effect of MeAIB on mIPSC amplitudes is reproduced at physiological 
temperature and with histidine 
A, Average mIPSC waveforms from a representative cell recorded at 34oC in control 
(black), in 10 mM MeAIB (gray) and after drug washout.  B, Average mIPSC waveforms 
from a representative cell in control (black), in 10 mM histidine (gray) and after drug 
washout.  Histidine is a non-selective inhibitor of SNATs.  Scale bars represent 10 pA 
and 20 ms in both panels.  C, Comparison of the effect of MeAIB at room and 
physiological temperatures with the effect of histidine on median mIPSC amplitudes.  
Number of cells is shown in parentheses. Error bars indicate SEM. 
 
 
 
63 
Since mIPSCs occur spontaneously in the absence of neuronal activity, we next 
asked whether these recorded events represent a pool of vesicles that is metabolically 
distinct from those released following an action potential. To address this question, we 
used hypertonic solution to evoke release of vesicles comprising the readily releasable 
pool (Rosenmund & Stevens 1996).  The effect of MeAIB on hyperosmotically-evoked 
mIPSC amplitudes was identical to its effect on spontaneous mIPSCs recorded in the 
same cells (p=0.5; n = 3 cells; Figure 10). 
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Figure 10.  MeAIB reduces both spontaneous and hyperosmotically-evoked mIPSCs 
A, Upper panel, Average spontaneously occurring mIPSC waveform in control solution 
(black) and in 10 mM MeAIB (gray) from a representative cell.  Lower panel, Average 
evoked mIPSC waveform during pressure application of 500 mM sucrose in control 
solution (black) and in MeAIB (gray) recorded in the same cell as the panel above.  Scale 
bars represent 10 pA and 20 ms.  B,  Comparison of the effect of MeAIB on spontaneous 
and evoked mIPSC amplitudes.  Error bars indicate SEM. 
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Previous studies demonstrated that exogenous glutamate increases mIPSC 
amplitudes via an effect of GABA synthesis (Mathews & Diamond 2003).  Therefore, we 
asked whether addition of exogenous glutamine would increase mIPSC amplitudes.  
Addition of glutamine (500 mM or 2 mM) to the perfusate had no effect on mIPSC 
amplitudes (39.8 ± 8.8 pA vs. 39.9 ± 11.4 pA:  p = 1.0, n = 5 cells; Figure 11), suggesting 
that the extracellular concentration of glutamine within the slice is sufficient to saturate 
neuronal glutamine uptake.  Since glutamine normally is absent from our perfusion 
solutions, we hypothesized that saturating levels of glutamine are maintained by 
astrocytes that take up extracellular glutamate to produce glutamine.  If this glutamate-
glutamine cycle mediated by astrocytes were the source of glutamine (Figure 12A), then 
we hypothesized that MeAIB would not reduce mIPSC amplitudes after the supply of 
glutamine from astrocytes was interrupted.   In the presence of L-methionine sulfoximine 
(MSO; 5 mM), an inhibitor of astrocytic glutamine synthetase, or of dihydrokainate 
(DHK; 300 µM), an inhibitor of the predominant astrocytic glutamate transporter 
EAAT2, MeAIB had no effect on mIPSC amplitudes (p=0.11, n = 8 for MSO; p=0.58, 
n=5 for DHK; Figure 12A, B).  Interestingly, DHK and MSO alone did not produce a 
reduction as would be expected if they only reduced glutamine supply from astrocytes to 
neurons.  However, unlike MeAIB, by impairing glutamate clearance by astrocytes, both 
MSO (Cavelier & Attwell 2005) and DHK (Munoz et al. 1987) raise extracellular 
glutamate levels.  We hypothesized that increased neuronal glutamate uptake, presumably 
via EAAT3 (see Figure 12A), counteracted the effect on GABA synthesis of DHK and 
MSO.  To test this hypothesis, we co-applied the non-selective EAAT inhibitor THA 
(300 mM) with DHK to eliminate EAAT3-mediated uptake, and observed a 17 ± 2 % 
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reduction in mIPSC amplitudes (p<0.001; n = 5 cells, Figure 12C).  Therefore, in support 
of the model whereby both glutamine and glutamate uptake each contribute to 
neurotransmitter GABA synthesis, the inhibition of EAAT3 in addition to EAAT2 
resulted in a reduction in mIPSC amplitudes comparable to MeAIB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
Figure 11.  Exogenous glutamine has no effect on mIPSC amplitudes 
A, Average mIPSC waveforms from a representative cell in control solution (black) and 
500 µM glutamine (gray).  Scale bars represent 10 pA and 20 ms.  B, Cumulative 
probability histograms of normalized mIPSC amplitudes in control solution (black 
symbols) and after addition of glutamine (gray symbols). Results with 500 mM or 2 mM 
glutamine were no different and were pooled together.  Data were averaged from 5 cells 
and error bars indicate SEM.  
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Figure 12.  Astrocytes provide glutamine for GABA synthesis 
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Figure 12.  Astrocytes provide glutamine for GABA synthesis 
A, Schematic model of the metabolic pathways regulating the synaptic pool of GABA.  
Astrocytes (shaded) take up synaptically-released glutamate (glu), synthesize glutamine 
(gln), and export gln for uptake by both excitatory and inhibitory neurons using 
SNAT1/2.  Glu for GABA synthesis can be converted from gln or can be taken up 
directly by EAAT3. Stars indicate the sites of action of DHK (white), MSO (black) and 
MeAIB (gray).  THA non-selectively inhibits EAAT2 and 3.  Abbreviations: GS, 
glutamine synthetase; GLS1, glutaminase type 1; GAD, glutamic acid decarboxylase; 
vGAT, vesicular GABA transporter; GAT1, GABA transporter 1; EAAT2 and 3, 
excitatory amino acid transporters 2 and 3.  B, Lack of effect of addition of MeAIB 
during application of MSO (5 mM, circles, dashed line) or DHK (300 mM, squares, 
dotted line) on median mIPSC amplitudes.  Error bars indicate SEM.  C, Summary of the 
effects of MeAIB, DHK, and the combination of DHK and THA.  Inhibition of EAAT2 
alone with DHK does not affect mIPSC amplitudes, but additional inhibition of EAAT3 
by THA produces a similar reduction compared with MeAIB.  Number of cells indicated 
in parentheses.  Error bars indicate SEM. 
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Discussion 
 
System A transporters provide glutamine for synaptic GABA synthesis 
Our results demonstrate that System A transporters on inhibitory neurons provide 
glutamine for neurotransmitter GABA synthesis.  Pharmacological inhibition of these 
neuronal glutamine transporters with the selective inhibitor MeAIB reduced evoked IPSC 
amplitudes, and, correspondingly, reversibly reduced mIPSC amplitudes in hippocampal 
slices.  We considered the possibility of a post-synaptic mechanism (i.e. a change in post-
synaptic sensitivity to GABA), but no effect of MeAIB on currents elicited by 
exogenously applied GABA was observed. Moreover, the effect of MeAIB was abolished 
in the presence of agents that interrupted astrocytic glutamine synthesis, which would not 
be predicted if MeAIB acted on post-synaptic targets.  Because of the relatively high 
concentration of MeAIB required to inhibit glutamine uptake, we were concerned with 
the possibility of non-specific effects.  However, a similar reduction in mIPSC 
amplitudes was observed using histidine, an amino acid that competes with glutamine at 
multiple neutral amino acid transporters, suggesting that glutamine transporters were in 
fact the target of MeAIB.  We also considered the possibility that the observed reduction 
in mIPSC amplitudes was the consequence of a pre-synaptic mechanism of action: either 
a reduction in vesicular GABA content or a decrease in the probability of vesicle release.   
To address the latter possibility we examined the effect of MeAIB on short-term synaptic 
plasticity, i.e. paired pulse ratios, which are interpreted to indicate changes in probability 
of release rather than in vesicular content.  In agreement with the lack of change in 
paired-pulse ratio in the presence of MeAIB, we also observed no change in mIPSC 
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frequency, another common indicator of release probability.  We therefore conclude, as 
in our earlier studies (Mathews & Diamond 2003), that the reductions in IPSC and 
mIPSC amplitude were due to an effect on GABA synthesis and, consequently, on 
vesicular content of GABA. 
In a recent study (Liang et al. 2006), a role for glutamine supply in synaptic 
GABA release from hippocampal interneurons was manifest only after repetitive burst 
stimulation lasting 15 minutes.  These results suggest that utilization of glutamine as a 
precursor for GABA synthesis occurs only when demand exceeds a resting level, 
although a threshold was not determined.  In that study, MeAIB (5 mM) or MSO (1.5 
mM) did not alter mIPSC amplitudes recorded in rat hippocampal CA1 pyramidal 
neurons.  We consistently found an effect of MeAIB in the absence of neuronal activity 
(i.e. mIPSCs recorded in TTX; Figure 8), regardless of temperature.   We also observed 
an effect of MeAIB on evoked IPSCs (Figure 7), which are recorded without blocking 
spontaneous synaptic activity, and the reduction in amplitudes was even greater than 
those seen in TTX (37% vs. 16% reduction, respectively).  Therefore, we propose that the 
contribution of System A-mediated glutamine uptake to GABA synthesis does correlate 
with the level of synaptic activity, but that a significant role for this supply of precursor 
exists even under resting conditions (i.e. no synaptic activity).  Perhaps our use of a 
higher (10 mM in our study vs. 5 mM) MeAIB concentration enabled us to detect these 
changes.  There also may be other methodological differences, including age of animals 
(1-2 weeks in our study vs. 6 weeks).  However, SNAT1 expression in rat hippocampal 
CA1 area is present as early as E17 and does not undergo obvious change with 
maturation (Weiss et al. 2003).  Still, developmental changes in dependence on glutamine 
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supply are an interesting possibility to explore especially in light of evidence that 
expression of another substrate transporter, EAAT3, actually decreases during maturation 
(Furuta et al. 1997). 
It is possible that MeAIB’s effect on GABA synthesis was indirect, due to an 
effect on the uptake of glutamine and a subsequent reduction in glutamate release by 
excitatory neurons, thereby reducing glutamate that may be transferred between 
excitatory and inhibitory synapses (see Figure 12A).  Glutamine is a source of 
neurotransmitter glutamate for excitatory neurons (Rothstein & Tabakoff 1984, Armano 
et al. 2002, Bacci et al. 2002), perhaps to a greater extent than for GABA (Szerb & 
O'Regan 1984).  However, the effect of MeAIB on mIPSCs occurred rapidly (within 5 
minutes) in the absence of neuronal activity (i.e. in TTX).  Therefore it is unlikely that 
any effect on glutamate release from excitatory neurons would be sufficient to explain 
our results. 
 
GABA vesicle content is dynamically regulated by supply of precursors 
Our study is the first to demonstrate rapid changes in synaptic vesicle filling by 
disrupting the normally continuous glutamine supply from astrocytes to inhibitory 
neurons.  In agreement with our conclusions, recent biochemical data indicate that GABA 
synthesis and vesicular filling are tightly coupled processes.  First, the GAD isoform 
GAD65 is associated with synaptic vesicles where it forms complexes with the vesicular 
GABA transporter vGAT (Hsu et al. 2000).  Second, newly synthesized GABA is 
packaged into vesicles preferentially over preformed GABA (Jin et al. 2003).  
Furthermore, unlike other neurotransmitter systems (eg. monoamines and glycine) that 
rely on reuptake to maintain neurotransmission, mice lacking the GABA reuptake 
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transporter GAT1 do not have impaired synaptic transmission (Jensen et al. 2003).  
Taken together with our results, these findings suggest that the GABA neurotransmitter 
system depends on synthesis more than reuptake.  Due to the multiple metabolic 
pathways used by inhibitory neurons (see Figure 12A), the GABA neurotransmitter 
system has more potential sites of regulation than other systems.  This study demonstrates 
that System A transporters, like EAAT3 (Mathews & Diamond 2003) and GAD (Engel et 
al. 2001), are key regulatory points at which inhibitory synaptic strength may be 
modulated by supply or metabolism of precursors. 
Because spontaneous mIPSCs may represent a pool of vesicles separate from the 
readily releasable pool (Sara et al. 2005), we considered the possibility that we were 
measuring effects of MeAIB on a metabolically distinct subset of vesicles that did not 
participate in the rapidly recycling pool.  Especially in light of a report that the 
requirement for glutamine in GABA synthesis is seen only after moderate stimulation 
(Liang et al. 2006), we speculated that glutamine may contribute only to a “reserve” pool 
of vesicles.  Although the experiments depicted in Figure 6 show an effect of MeAIB on 
action potential-dependent release of GABA, we addressed this issue further by 
“evoking” mIPSCs with hyperosmolar solution in the presence of TTX, causing release 
of readily releasable vesicles.  The amplitude reduction of these evoked mIPSC was 
reduced identical to that of the spontaneous pool, suggesting that the dependence on 
glutamine supply applies to all synaptic vesicles. 
Glutamine is normally present at a high concentration (0.5 – 1 mM) in the 
cerebrospinal fluid (McGale et al. 1977) and in vivo microdialysis studies indicate that 
similar levels exist extracellularly in awake rat brains (Kanamori & Ross 2004).  It is 
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likely that locally even higher concentrations exist, since astrocytic processes containing 
SNAT3, one of the transporters capable of mediating glutamine efflux (Figure 12A), 
ensheath GABAergic axon terminals (Boulland et al. 2002).  Given the affinities of 
SNAT1 and 2 for glutamine [KM = 0.5 and 1.6 mM, respectively; (Varoqui et al. 2000, 
Yao et al. 2000)], these transporters may operate at or near saturation under normal 
conditions.  Addition of exogenous glutamine did not increase the GABA content of 
vesicles, supporting this conclusion.  It is also possible that the enzyme that converts 
glutamine to glutamate, possibly GLS-1, is saturated rather than the transporters, and our 
experiments do not allow us to distinguish between these possibilities.  It should be noted 
that immunohistochemical studies have demonstrated only rare localization of SNAT1 
and SNAT2 to axon terminals in cortex (Conti & Melone 2006).  Our results with MeAIB 
suggest that the location of System A transporters on inhibitory neurons is sufficiently 
near to synaptic terminals to rapidly influence neurotransmitter GABA metabolism. 
In contrast to glutamine, glutamate applied exogenously, at concentrations higher 
than its normally very low extracellular level, increases the GABA content of vesicles 
(Mathews & Diamond 2003).  Therefore, although System A transporters appear to be 
saturated, GAD has excess capacity allowing GABA synthesis to be up- as well as down-
regulated by substrate supply.  Extracellular levels of glutamate can bi-directionally 
regulate GABA vesicle content (Mathews & Diamond 2003), and local glutamate levels 
fluctuate with excitatory synaptic activity.  Because extracellular glutamate levels are 
normally well below the KM of EAAT3, we propose that glutamate uptake via EAAT3 is 
sensitive to excitatory activity, particularly in the hippocampal area CA1 where 
excitatory and inhibitory synapses lie in close proximity (Megias et al. 2001).  In support 
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of this, in our previous work using protocols entailing relatively higher levels of synaptic 
activity (i.e. periodically evoked responses in the presence of strontium; (Mathews & 
Diamond 2003), blocking glial clearance of glutamate with DHK actually increased 
vesicle GABA content due to a relatively greater effect on extracellular glutamate that 
resulted in increased neuronal glutamate uptake.  In this study, with synaptic activity 
blocked, DHK increased neuronal glutamate uptake sufficiently to counteract its effect on 
the glutamine pathway, as evidenced by our results with DHK in combination THA, 
resulting in no net change in vesicle content due to DHK alone. 
We suggest that two independent substrate supply pathways exist for the synthesis 
of neurotransmitter GABA, mediated by SNAT1 or SNAT2 and EAAT3 (Figure 12A), 
and that both contribute to a dynamic equilibrium of synthesis and vesicular content.  
Their relative contributions are related both to the level of synaptic activity (and therefore 
glutamate release) and possibly to the intrinsic regulation of the transporters themselves.  
Changes in surface expression have been described for EAAT3 in response to activation 
of several signal transduction pathways (Fournier et al. 2004) and during LTP induction 
(Levenson et al. 2002), but similar regulation of SNATs in neurons remains to be 
explored.   If System A transporters on inhibitory neurons are indeed saturated normally, 
then upregulation of SNAT expression is one potential mechanism by which 
enhancement of inhibition may be achieved in response to cellular signals. 
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CHAPTER III 
 
ACTIVITY- AND AGE-DEPENDENT MODULATION OF GABAERGIC 
NEUROTRANSMISSION BY SNAT1-MEDIATED GLUTAMINE UPTAKE 
 
Introduction 
 
Normal brain function requires that inhibitory GABAergic systems adapt to a 
range of activity states, and increased demand for neurotransmitter GABA must be met 
with increased synthesis or seizures may result (Sepkuty et al. 2002, Kash et al. 1997).  
Because neurons are not capable of net production of glutamate, GABA’s immediate 
metabolic precursor, interneurons rely on a supply of glutamate to maintain GABA 
synthesis and vesicular filling.  Glutamine, which is cycled between astrocytes and 
neurons, can be converted to glutamate in neurons.  Therefore, substrate transporters 
supplying either glutamate or glutamine may play a key role in linking activity-related 
demand for GABA to its rate of synthesis (see Figure 15A).  The sodium-coupled neutral 
amino acid transporters SNAT1 and SNAT2 comprise “System A” that mediates most 
neuronal glutamine uptake (Broer & Brookes 2001), but whether either one plays an 
active role in shaping neurotransmission has not been determined. 
 Some studies suggest that System A-mediated glutamine uptake contributes to 
neurotransmitter pools only under conditions of increased metabolic demand (Tani et al. 
2007, Bryant et al. 2009, Liang et al. 2006).  However, inhibition of System A 
transporters rapidly reduces vesicular GABA content in immature hippocampal 
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interneurons under resting conditions (Fricke et al. 2007).  Therefore, we investigated 
whether System A-mediated glutamine uptake can be regulated in order for interneurons 
to adapt to increased demand for GABA.  Other elements involved in GABA synthesis 
(see Figure 15A) could also be regulated to influence inhibitory neurotransmission; 
however, because a concentration of glutamine capable of saturating System A 
transporters is available to neurons normally (McGale et al. 1977, Fricke et al. 2007), we 
hypothesized regulation of the surface activity of System A transporters would be an 
effective mechanism to modulate glutamine supply, GABA synthesis and vesicular 
GABA content.  Moreover, because of the critical role of GABA signaling in 
coordinating excitatory synapse maturation and synaptogenesis (Wang & Kriegstein 
2009, Ben-Ari et al. 2007), we hypothesized that the role of System A transporters at 
inhibitory synapses also may be developmentlally regulated.  
 Using electrophysiology in hippocampal slices in conjunction with protein 
expression studies and uptake assays in synaptosomes, we demonstrate that System A 
transporters serve both a constitutive and activity-dependent role in modulating vesicular 
GABA content and inhibitory synaptic strength.  Synaptic depolarization up-regulates the 
surface activity of System A transporters and thus induces an increase in vesicular GABA 
content in both immature and mature hippocampus.  However, because System A’s basal 
uptake activity and therefore its constitutive contribution to vesicular GABA content 
diminishes over the first two postnatal weeks, its role in mature hippocampus is only 
manifest in an activity-dependent manner.  Furthermore, our results support that these 
constitutive and activity-dependent roles are likely mediated by the SNAT1 subtype of 
System A transporters.  Therefore, our results strongly support the hypothesis that the 
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surface activity of SNAT1, regulated both by depolarization and by developmental cues, 
is the key component in a novel mechanism to dynamically link metabolic demand for 
GABA with vesicular GABA content and inhibitory synaptic strength. 
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Experimental Procedures 
 
Materials 
α-(Methyl-amino) isobutyric acid (MeAIB), 3-Mercaptoproprionic acid (3-MPA), 
(1,2,5,6-Tetrahydropyridin-4-yl) methylphosphinic acid hydrate (TPMPA), 6,7-
dinitroquinoxaline-2,3-dione (DNQX), CPG55845, and dizocilpine maleate (MK-801) 
were obtained from Sigma (St. Louis, MO, USA).  Tetrodotoxin (TTX) was obtained 
from Tocris (Ellisville, MO, USA).  [3H]MeAIB was obtained from American 
Radiolabeled Chemicals.  Jeffrey Erickson (LSU Health Sciences Center, New Orleans, 
LA) provided the rabbit polyclonal anti-SNAT1 (1:14,000) and anti-SNAT2 (1:1,000) 
antibodies used for western blot analysis and both antibodies have been characterized 
previously for specificity in rat brain (Varoqui et al. 2000, Yao et al. 2000).  Additional 
antibodies used for western blot analysis include rabbit anti-EAAC1, 1:1000 (Alpha 
Diagnostic International); rabbit anti-GAT-1, 1:200 (Chemicon); mouse anti-GAD65, 
1:500 (Chemicon); mouse anti-actin, 1:800,000 (Chemicon).   
 
Preparation of hippocampal slices and patch clamp recording 
 Sprague Dawley rats at various ages were deeply anesthetized with isoflurane and 
decapitated under a protocol approved by Vanderbilt University’s Institutional Animal 
Care and Use Committee.  Hippocampi were removed and cut into 400µm sections using 
a vibratome (Vibratome Company, St. Louis, MO, USA) in an ice-cold oxygenated 
solution containing (in mmol/L): sucrose 75, NaCl 87, KCl 2.5, MgCl2 7, CaCl2 0.5, 
NaH2PO4 1.25, glucose 25, and NaHCO3 25.  Slices were transferred to a chamber 
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containing artificial cerebrospinal fluid (ACSF), which contained (in mmol/L): NaCl 119, 
KCl 2.5, MgCl2 1.3, CaCl2 2.5, NaH2PO4 1, glucose 11, and NaHCO3 26.2, (pH 7.4, 
290mOsm) and bubbled with 95% O2/5% CO2.  Slices were incubated at 35°C for 30 
min, then at room temperature (22-25°C) for 30 min before recording. 
 Patch pipettes with resistances of 3-5MΩ were filled with a solution containing 
(in mmol/L): cesium chloride 130, HEPES 10, EGTA 10, lidocaine N-ethyl bromide 
(QX-314) 1, Na2+-GTP 0.2, and Mg2+-ATP 2 (pH 7.4, 290 mOsm).  For studies 
investigating the effects of high K+-induced depolarization, KCl replaced cesium chloride 
and QX-314 was witheld from the solution.  Whole cell recordings were obtained at a 
holding potential of -60mV with a MultiClamp 700A amplifier (Molecular Devices 
Corporation, Sunnyvale, CA, USA).  Access resistance was monitored throughout the 
experiment and data were discarded if increase was more than 20%.  Slices were perfused 
constantly at approximately 2 mL/min with ACSF (bubbled with 95% O2/5% CO2).   
Miniature inhibitory postsynaptic currents (mIPSCs) were recorded by adding TTX 
(0.5µmol/L), DNQX (10 µmol/L), and MK-801 (5µmol/L) to the recording solution.  All 
experiments were performed at 22-25°C unless otherwise indicated. 
 After control currents were obtained, the effects of MeAIB, TPMPA or glutamine 
were evaluated after a 5 minute wash-in period.  For TPMPA studies, CPG55845 
(300nmol/L), a GABAB receptor antagonist, was included in the perfusate to block 
activity of TPMPA at GABAB receptors.  For studies in which glutamic acid 
decarboxylase was inhibited, slices were incubated for 1h in 3-MPA (1mmol/L), then 
transferred to the recording chamber where the perfusate contained 250µmol/L 3-MPA.  
For experiments evaluating the effect of hyperexcitable state, slices were exposed to 
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2.5mmol/L KCl-ACSF (sham) or 10mmol/L KCl-ACSF (high K+) for 20 minutes at 
room temperature and then transferred to the recording chamber where the remainder of 
the experiment was performed at 34°C.  Slices were perfused with their respective ACSF 
for 10-20 minutes while a suitable patch clamp recording was obtained and when the 
whole-cell configuration was achieved, the level of neuronal activity was monitored in 
current clamp for an additional 5 minutes (eg. Figure 14A).  After this period, the 
perfusate for all slices was replaced with 2.5mmol/L KCl-ACSF containing TTX, 
DNQX, and MK-801.  Therefore, all recorded neurons had a period of at least 5 minutes 
after whole-cell recording configuration was achieved to allow equilibration of the 
intracellular and pipette solution contents prior to recording mIPSCs which would be 
sufficient to exclude potential variations in intracellular chloride concentration between 
neurons in sham and high K+ treated slices that could have confounded our results.  For 
studies examining the effect of TPMPA or MeAIB on mIPSCs after sham treatment or 
high K+-induced depolarization, we recorded mIPSCs at one-minute, washed-in TPMPA 
or MeAIB for 5 minutes, and assessed the drug effects on mIPSCs recorded at ten 
minutes post-depolarization (see Figure 14B).  
 
Immunohistochemistry 
Postnatal day 8 and 25 Sprague-Dawley rats were deeply anesthetized with sodium 
pentobarbital.  Transcardiac perfusion with 0.9% saline followed by a solution of 4% 
paraformaldehyde (freshly prepared, pH 7.2) was performed.  Brains were post-fixed 
overnight at 4°C.  Coronal sections (40 µm) were cut using a freezing microtome (Leica 
Microsystems, Germany).  A mouse monoclonal anti-SNAT1 (N104/37) antibody was 
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used for immunohistochemistry (NeuroMabs, UC Davis).  Both N104/37 and the rabbit 
polyclonal anti-SNAT1 antibodies recognized a 52kD band in immunoblots and their 
binding was blocked by preadsorption with the control peptide (data not shown).  In 
addition, both SNAT1 antibodies displayed the same staining pattern in immature and 
mature hippocampus - a population of non-pyramidal neurons without appreciable 
staining of pyramidal neurons - although the rabbit polyclonal antibody demonstrated 
higher background staining (Figure 13).  Immunohistochemistry was performed with 
free-floating sections blocked in 4% milk then incubated for 72 hours at 4°C in primary 
antibody.  An optimal antibody dilution of 1:1000 was determined by evaluation of 
immunostaining over a range of dilutions.  For secondary detection, sections were 
incubated in biotinylated anti-rabbit IgG (1:1000, Jackson Immunoresearch, West Grove, 
PA) for one hour at room temperature, then with avidin–biotin amplification reagent with 
horseradish peroxidase (Vectastain Elite ABC, Vector Laboratories, Burlingame, CA).  
Detection of horseradish peroxidase activity was achieved with the 3,3'-diaminobenzidine 
reaction. 
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Figure 13.  Rabbit polyclonal anti-SNAT1 and Mouse monoclonal anti-SNAT1 
antibodies stain similar populations of non-pyramidal neurons in area CA1 of 
hippocampus 
A, B, Both the mouse monocolonal anti-SNAT1 antibody (A) and the rabbit polyclonal 
anti-SNAT1 antibody (B) label a similar population of non-pyramidal neurons in area 
CA1 of rat hippocampus (P22) under identical conditions.  The rabbit polyclonal anti-
SNAT1 antibody demonstrated higher background staining.  Scale bar represents 20µm. 
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Western Blot Analysis 
Hippocampi were dissected from Sprague-Dawley rats at the postnatal day 
indicated, immediately frozen by dry ice, weighed, and stored at -80°C.  Frozen tissue 
was placed in ice-cold solution (15µL/mg) containing 2% SDS and a protease inhibitor 
cocktail (1:1000, Sigma) and sonicated (Sonics Vibra Cell, Sonics & Materials, Inc., 
Newtown, CT).  Protein concentrations were determined using the colorimetric DC 
Protein Assay (Bio-Rad).  Samples were diluted 1:1 in 2X sample buffer (0.125M Tris 
base, 10% SDS, 10% glycerol, 0.02% Bromophenol blue, 4% β-mercaptoethanol, pH 
6.8) and stored at -80°C.  Equal amounts of protein (20µg for GAT-1 experiments, 10µg 
for all remaining experiments) were loaded on a 10% Tris-Glycine polyacrylamide gel.  
After electrophoretic separation, proteins were transferred to a PVDF membrane.  
Membranes were blocked with 5% milk plus 0.1% Tween 20 for 1 hour at room 
temperature, and incubated with the respective primary antibody overnight at 4°C.  After 
several washes in PBS plus 0.1% Tween 20, membranes were incubated in horseradish 
peroxidase-conjugated secondary antibodies (1:20,000, Jackson Laboratories, Inc.) for 1 
hour at room temperature.  After several washes in PBS plus 0.1% Tween 20, membranes 
were developed with enhanced chemiluminescence reagents (ECL kit, Amersham) and 
then exposed to autoradiography film (Denville Scientific, Inc.).  Measurements of each 
protein were conducted in the same sample, and all experiments were repeated in three 
different animals at each age.   
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Preparation of synaptosomes and [3H]MeAIB uptake assays 
Crude synaptosomes were prepared by dissecting hippocampi from immature (P8-
11) and mature (P21-28) Sprague-Dawley rats which were immediately immersed in 
3mL of an ice-cold solution containing (in mmol/L): sucrose 320, NaCl 119, KCl 2.5, 
MgCl2 1.3, CaCl2 2.5, NaH2PO4 1, glucose 11, and HEPES 10.  Tissue was homogenized 
at 400 rpm using a Teflon-glass tissue homogenizer (Wheaton Instruments, Millville, NJ) 
followed by centrifugation at 2000 rpm for 10 minutes at 4°C.  The supernatant was 
transferred to clean centrifugation tubes and centrifuged at 13,000 rpm for 15 min at 4°C.  
After discarding the supernatant, the pellet was re-suspended in 1 mL ACSF (10mM 
HEPES replacing NaHCO3) and analyzed for protein concentration (Bio-Rad protein 
assay reagent, 1:5).  For western blot analysis, synaptosomes were diluted 1:1 in sample 
buffer and probed for SNAT1, GAD65, and actin according to conditions specificed 
above.  For uptake assays, samples containing 325µg protein each were incubated for 10 
minutes (unless otherwise indicated) in a shaking water bath at 37°C prior to the addition 
of [3H]MeAIB (167nmol/L; specific activity, 60Ci/mmol).  After a 2.5 minute incubation, 
[3H]MeAIB uptake was terminated by adding 1 mL ice-cold ACSF (choline chloride 
replacing sodium chloride).  Uptake after high K+-induced depolarization was examined 
according to the protocol published in (Ferguson et al. 2003).  Samples were incubated in 
sham (2.5mmol/L KCl) or high potassium (10mmol/L KCl) ACSF for 15 minutes in a 
shaking water bath at 37°C.  Samples were then immediately centrifuged at 13,000rpm 
for 2 minutes, their supernatants were discarded, and the pellets were resuspended with 
sham ACSF.  All samples incubated in a shaking 37°C water bath for either 1 or 10 
minutes prior to the addition of 167nmol/L [3H]MeAIB for 2.5 minutes.  Samples were 
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collected onto 0.3% polyethylenimine-coated glass fiber filters and washed three times 
with ice-cold ACSF using a Brandel cell harvester.  Filters were immersed in scintillation 
fluid overnight and radioactivity was counted by scintillation spectrometry.  All uptake 
assays were performed in triplicate and specific MeAIB uptake was determined by 
subtracting uptake in parallel samples prepared in ACSF where choline chloride replaced 
sodium chloride.    
 
Data analysis 
Electrophysiology 
Individual mIPSCs meeting threshold criteria were detected using MiniAnalysis software 
(Synaptosoft, Fort Lee, NJ, USA) and visually inspected to exclude artifacts.  Those 
single events arising from a stable baseline were used for analysis.  At least 100 events 
were recorded from each cell in each condition, and the median was calculated.  Each 
experiment was performed in multiple cells (‘n’) prepared from at least three animals.  
Assessment of pharmacological or high K+ effects are reported as either a percent change 
from baseline ± SEM, a percent control of baseline ± SEM or a mean of the median 
mIPSC amplitude ± SD.  Decay time constants were calculated for the mean of the 
median mIPSC amplitude (pClamp, Molecular Devices) and reported as either a single or 
weighted tau (F-test performed to assess best fit).  Data evaluating drug or high K+ effects 
were compared using a student’s paired t-test unless otherwise indicated.  Correlations 
between mIPSCs with time (Table 2) were assessed using Spearman’s Rank Order 
Correlation Test. 
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Western Blot Analysis 
Band intensity was measured with ImageJ software and normalized to the actin 
band for each protein.  To compare the relative expression of SNAT1, EAAT3, and 
GAT-1 across development, we determined the ratio of each protein’s level to that for 
GAD65  (also normalized to actin) to account for the formation and maturation of 
GABAergic synapses occurring during this time.  Correlations between SNAT1 or 
SNAT2 protein expression with time were assessed using Spearman’s Rank Order 
Correlation Test and developmental differences between the SNAT1:GAD65 protein 
ratio in synaptosomes were assessed using a student’s t-test.   
 
[3H]MeAIB uptake assays 
MeAIB uptake following high K+-induced depolarization was normalized to the 
respective sham control and reported as a percent of control ± SEM.  Statistical 
significance for both [3H]MeAIB uptake experiments was assessed using a student’s t-
test.   
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Results 
 
System A-dependent increase in quantal size after hyperexcitable state due to increased  
vesicular GABA content 
 Recent studies have demonstrated that neurons rely on glutamine supplied by 
System A transporters to sustain their neurotransmitter pools during periods of increased 
metabolic demand (Bryant et al. 2009, Liang et al. 2006, Tani et al. 2007).  Because 
extracellular glutamine concentration is sufficient to saturate System A transporters, 
glutamine uptake is likely to be a key regulatory point within the glutamate-glutamine-
GABA (glu-gln-GABA) pathway (see Figure 15A) capable of dynamically modulating 
vesicular GABA content.  Consequently, we hypothesized that the glutamine supply to 
inhibitory synapses could be regulated through the surface activity of System A 
transporters.  Evidence that individual synaptic vesicles do not contain enough GABA to 
saturate postsynaptic receptors in hippocampus has been provided by studies showing 
that the amplitude of mIPSCs directly varies within a certain range of GABA 
concentrations within the synaptic cleft ([GABA]cleft), correlating with changes in 
vesicular GABA content (Mathews & Diamond 2003, Stafford et al. 2009, Hartmann et 
al. 2008). 
 We induced a hyperexcitable state in hippocampal slices by transiently elevating 
extracellular potassium, and we assessed quantal size immediately afterwards by 
recording mIPSCs in CA1 pyramidal neurons.  Slices that were placed in ACSF 
containing 10mmol/L KCl (hereby termed high K+-induced depolarization) demonstrated 
hyperexcitability that was characterized by a depolarization of the membrane potential by 
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approximately 15mV as well as an increase in the frequency of both action potentials and 
synaptic potentials recorded in the CA1 pyramidal neuron (Figure 14A).  Sham treated 
slices were exposed to the identical protocol except control ACSF containing 2.5mmol/L 
KCl was substituted for the high K+ ACSF.  Following the 30 minute incubation, 
tetrodotoxin was added to the recording solution (control ACSF) and mIPSCs were 
recorded after allowing sufficient time for equilibration of the patch pipette solution with 
the intracellular contents (Figure 14B).  In slices from immature (P8-12) rats, mIPSC 
amplitudes increased from 34 ± 9 pA immediately after high K+-induced depolarization 
to 41 ± 12 pA ten minutes after depolarization (p<0.05, n=7; Figure 14Ci).  This increase 
is reflected in a shift in the distribution of mIPSC amplitudes toward larger amplitudes at 
ten minutes post-depolarization (p<0.01, KS test; Figure 14Cii).  The increase in quantal 
size was due to the high K+ as no change in mIPSC amplitudes was observed following 
sham treatment (p=0.3, n=4; data not shown).  Similarly, in mature (P21-28) slices, 
mIPSC amplitudes were increased from 32 ± 6 pA to 39 ± 7 pA ten minutes after high 
K+-induced depolarization (p<0.05, n=7; Figure 14Di) and the amplitude distribution was 
shifted toward larger values (p<0.01, KS test; Figure 14Dii).  No change in mIPSC 
amplitudes was observed following sham treatment (p=0.9, n=3; data not shown).    
Since an increase in quantal size may result from either presynaptic or 
postsynaptic changes, we sought to distinguish between a change in synaptic [GABA]cleft 
and a change in post-synaptic receptor number or sensitivity by examining the effect of 
TPMPA on mIPSC amplitudes following high K+-induced depolarization.  TPMPA is a 
weak competitive antagonist at GABAA receptors characterized by a dissociation time 
constant that is more rapid than the syaptic cleft transient of GABA (Jones et al. 2001).  
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As a result, TPMPA’s efficacy is very sensitive to synaptic [GABA]cleft and therefore to 
changes in vesicular GABA content (Liang et al. 2006, Hartmann et al. 2008).  We first 
determined the concentration of TPMPA required to reduce mIPSC amplitudes by the 
same amount at each age following sham treatment.  There was a slight difference in the 
concentration needed to reduce mIPSCs by 20-25% (Immature: 100µmol/L, 21 ± 4%, 
n=5; Mature: 85µmol/L, 26 ± 3%, n=5; Figure 14E), suggesting the baseline synaptic 
[GABA]cleft is dependent of developmental age.  If the increase in quantal size following 
high K+-induced depolarization were due to an elevation in synaptic [GABA]cleft, 
TPMPA’s efficacy should be proportionally reduced.  In both immature and mature 
slices, the effect of TPMPA on mIPSC amplitudes after high K+-induced depolarization 
was reduced compared with its effect in sham treatment (Immature: +4 ± 5%, p<0.01, 
n=5; Mature: -4 ± 8%, p<0.05, n=5; student’s t-test, Figure 14E), consistent with 
augmented vesicle content and synaptic [GABA]cleft producing the observed increase in 
quantal size. 
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Figure 14.  Synaptic depolarization augments quantal size due to increased vesicular 
GABA content 
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Figure 14.  Synaptic depolarization augments quantal size due to increased vesicular 
GABA content 
A, Representative action potential and spontaneous postsynaptic potential waveforms 
recorded from an immature CA1 pyramidal neuron during sham-treatment (2.5mmol/L 
KCl) or high K+-induced depolarization (10mmol/L KCl).  Note the approximate 15mV 
depolarization in the resting membrane potential.  Scale bars represent 10mV and 1s.  B, 
Time line of experimental protocol for high K+-induced depolarization of hippocampal 
slices.  Ci, Di, Representative averaged mIPSC waveforms at 1, 5, and 10 minutes 
following high K+-induced depolarization.  Scale bars, 10pA and 20ms.  Cii, Dii, 
Cumulative probability histograms (n=7) of mIPSC amplitudes measured at 1 and 10 
minutes following high K+-induced depolarization of slices from immature (C) and 
mature (D) rats.  E, Comparison of the effect of TPMPA on mIPSC amplitudes reported 
as % block by TPMPA following sham-treatment or high K+-induced depolarization.  
The % block was determined by calculating the % change in mIPSC amplitudes at ten 
minutes compared with mIPSC amplitudes recorded within the first minute following 
high K+.  See text for ‘n’; Error bars, SEM.   
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In both immature and mature slices, the increase in vesicular GABA content 
correlates with a time-dependent increase in mIPSC amplitudes, which peaked at ten 
minutes following high K+-induced depolarization followed by a return to baseline values 
(Immature: p<0.01, n=7; Mature:, p<0.05, n=7; Repeated Measures ANOVA, Figure 
15B,C).  Consistent with a specific correlation, we observed no change in mIPSC 
amplitudes at any time following sham treatment (Immature: p=0.6, n=4; Mature: p=1.0, 
n=3; Repeated Measures ANOVA, Figure 15B,C).  In order to determine if the increase 
in vesicular GABA content required uptake of glutamine via System A transporters, we 
tested the effect of MeAIB, a specific inhibitor of System A transporters, on mIPSC 
amplitudes following high K+-induced depolarization.  With an apparent affinity of 0.5-
1.1mmol/L (Mackenzie et al. 2003, Yao et al. 2000), MeAIB has been used at 5–
50mmol/L to selectively inhibit System A transporters in a variety of in vitro studies 
(Bacci et al. 2002, Rae et al. 2003, Liang et al. 2006, Fricke et al. 2007).  MeAIB 
(10mmol/L) blocked the increase in mIPSC amplitudes following high K+-induced 
depolarization in both immature (p=0.2, n=5; Figure 15B) and mature (p=0.9, n=5; 
Figure 15C) slices.  These results suggest that the increase in vesicular GABA content 
required an ongoing supply of glutamine via System A transporters after the 
hyperexcitable period had ended.   
 A glutamine-dependent increase in synaptic GABA during periods of 
depolarization and increased neuronal activity could be mediated by an up-regulation of 
multiple elements within the glu-gln-GABA pathway (Figure 15A).  However, because 
extracellular glutamine concentrations are capable of saturating System A transporters 
[(Fricke et al. 2007); see also Figure 19 below], we hypothesized that synaptic 
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depolarization could increase the surface activity of System A transporters, thereby 
increasing glutamine uptake and supply, GABA synthesis and vesicular GABA content.  
We also hypothesized that regulation of the activity of the physiologically relevent pool 
of System A transporters could be observed directly in synaptosomal membranes.  To test 
these hypotheses, we measured the uptake of [3H]MeAIB after high K+-induced 
depolarization compared with sham treatment (analogous conditions to the slice 
experiments) in synaptosomes prepared from both immature and mature hippocampus.  
High K+-induced depolarization increased [3H]MeAIB uptake to 183 ± 31% of control 
(p<0.05, n=7) at one minute and to 151 ± 34%  (p=0.2, n=9) at ten minutes in immature 
synaptosomes (Figure 15D).  In mature synaptosomes, [3H]MeAIB uptake was increased 
at ten minutes after high K+-induced depolarization to 206 ± 43% (p<0.05, n=5; Figure 
15E).  Therefore, depolarization of synaptic membranes increased System A uptake 
activity within a similar time frame observed for augmentation of mIPSC amplitudes in 
intact slices. 
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Figure 15.  Synaptic depolarization augments System A surface activity to increase 
vesicular GABA content and inhibitory neurotransmission 
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Figure 15.  Synaptic depolarization augments SNAT1 surface activity to increase 
vesicular GABA content and inhibitory neurotransmission 
A, Schematic illustration of GABA biosynthetic pathways.  GAD65 and the vesicular 
GABA transporter (vGAT) are part of a complex of proteins that link GABA synthesis 
and vesicular filling.  Neurons acquire glutamate through direct uptake by EAAT3 or 
through the glutamate-glutamine-GABA pathway.  In this pathway, astrocytes uptake 
glutamate via EAAT2, convert it to glutamine, and export glutamine via System N 
transporters for neuronal uptake by System A transporters.  Neurons convert glutamine 
back to glutamate.  B, C, Timecourse displaying the % of control mIPSC amplitudes 
across time following sham treatment (black circles), high K+-induced depolarization 
(white circles) or high K+ after 10mmol/L MeAIB (gray circles).  The % of control 
mIPSC amplitude was calculated by normalizing the average median mIPSC amplitudes 
at each reported timepoint to the mIPSC amplitude at 1 minute.  D, E, Comparison of 
[3H]MeAIB uptake reported as % of control at 1 or 10 minutes after high K+-induced 
depolarization.  Bar width reflects incubation time of [3H]MeAIB (2.5m).  A-D, See text 
for ‘n’, *p<0.05; Error bars, SEM.   
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System A glutamine uptake contributes constitutively to synaptic GABA in an age-
dependent manner 
 Thus far our results demonstrate that System A-mediated glutamine uptake is 
intrinsically regulated to rapidly augment GABA synthesis and quantal size after synaptic 
depolarization.  Although the regulated role of System A did not differ between immature 
and mature hippocampus, we considered that the overall contribution of glutamine uptake 
to synaptic GABA might change during the course of developmental changes.  In 
particular, we asked whether System A transporters constitutively supply glutamine for 
GABA synthesis, particularly early in development when GABA serves a major role in 
hippocampal synapse maturation and synaptogenesis, and whether System A’s role 
changed during postnatal maturation.  To address these questions, we examined the effect 
of MeAIB (10mmol/L) on mIPSC amplitudes in hippocampal slices at sequential 
postnatal ages.  In immature slices, MeAIB rapidly reduced mIPSC amplitudes, 
consistent with System A transporters constitutively supplying glutamine for ongoing 
vesicular GABA synthesis (Figure 16).  However, by the second postnatal week, the 
effect of MeAIB abruptly diminished and was absent in mature slices (Table 2, Figure 
16).  We concluded that the age-dependent change in MeAIB’s effect on mIPSC 
amplitude (p<0.05) reflected a reduction in the constitutive contribution of glutamine 
uptake to vesicular GABA content and hypothesized that it could correlate with a change 
in the activity of System A transporters.  
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Figure 16.  Age-dependent loss of the contribution of System A-mediated glutamine 
uptake to vesicular GABA content 
A, Average mIPSC waveforms from a representative cell in control (black) and after 5 
minutes in 10mM MeAIB at sequential postnatal ages.  Scale bars, 10pA and 20ms.  B, 
Plot demonstrating the age-dependent effect of MeAIB on mIPSC amplitudes.  Each 
point represents the average percent change from baseline across a range of postnatal 
ages (n=7) (see Table 1).  **p<0.01, *p<0.05; Error bars, SEM.     
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Table 2 
 
 
 
 
 
 
 
 
 
Percent Change in mIPSC Characteristics in MeAIB 
Age Amplitude Decay Frequency 
P7-8 (n=7) -19 ± 3** +6 ± 6 +76 ± 28* 
P10-12 (n=7) -17 ± 6* -6 ± 5  +48 ± 28 
P14-15 (n=7) -4 ± 3 +9 ± 5 +53 ± 19 
P16-18 (n=7) -2 ± 5 +20 ± 18 +19 ± 22 
P22-25 (n=7) +2 ± 3 +2 ± 5 +33 ± 8* 
P42-44 (n=4) +9 ± 6 +7 ± 13 +37 ± 53 
Values are mean ± SEM.  *p<0.01 and **p<0.001.   
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We tested several alternative mechanisms that could explain the loss of MeAIB’s 
effect on mIPSC amplitudes in mature slices.  We considered that during maturation, 
System A-dependent glutamine uptake could become restricted to a sub-population of 
inhibitory synapses, and our statistical methods could fail to detect a change in mIPSC 
amplitudes in only a subpopulation of synapses.  To address this possibility, we assumed 
that subpopulations of synapses have similar quantal sizes and thus we grouped mIPSCs 
into amplitude quartiles.  We found that while MeAIB uniformly reduced mIPSC 
amplitudes in each quartile in immature slices (P7-8; p<0.05 in each quartile), mIPSC 
amplitudes were not reduced in any quartile in mature slices (data not shown).  We also 
considered that if MeAIB reduced the probability of vesicle release or altered 
postsynaptic membrane properties, and these “non-specific” effects were somehow age-
dependent, we should observe an effect of MeAIB on mIPSC frequency or mIPSC shape 
(eg. rate of decay) correlating with postnatal age.  However, we did not observe a 
correlation between postnatal age and either mIPSC frequency (p=0.5) or mIPSC decay 
time constant (p=0.8) (Table 2).  Therefore, the most likely conclusion is that the age-
dependent reduction in System A’s constitutive contribution of glutamine to synaptic 
GABA is due to a uniform loss of System A-dependent uptake at mature inhibitory 
synapses. 
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System A activity at inhibitory synapses mediates an age-dependent loss of glutamine’s 
contribution to vesicular GABA  
 To test the hypothesis that there is an age-dependent loss in the constitutive 
surface activity of System A transporters, we assayed both the expression and the activity 
of System A transporters. We first asked where SNAT1 and SNAT2 protein were 
expressed and whether there was a change in their expression in hippocampal area CA1 
during maturation.  We found that SNAT1 was expressed selectively in a population of 
non-pyramidal neurons in area CA1, and that this pattern was indistinguishable between 
immature and mature hippocampus (Figure 17A).   We did not observe a clear cell-
specific pattern of SNAT2 expression (data not shown). 
 Next we measured total SNAT1 and SNAT2 protein in whole hippocampal 
lysates at sequential postnatal ages using a semiquantitative Western blot approach.  
SNAT1 protein was highly expressed in immature hippocampus, and gradually decreased 
throughout postnatal development to adult levels (p<0.001, n=3; Figure 17B), paralleling 
the age-dependent loss of System A’s constitutive contribution of glutamine to synaptic 
GABA (Figure 15).  In contrast to SNAT1, the immature hippocampus expressed a low 
amount of SNAT2 protein that increased to adult levels (n=3; Figure 17).   Although we 
normalized our SNAT measurements to actin levels, because SNAT1 expression 
appeared restricted to interneurons, we considered the level of glutamic acid 
decarboxylase 65, (GAD65), the synaptic isoform of GAD, to be a more appropriate 
comparison for the physiological relevance of the age-dependent change in SNAT1 
expression.  In agreement with reports that the number of GABAergic synapses rapidly 
expands in hippocampus during the first three postnatal weeks (Danglot et al. 2006), we 
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found that GAD65 expression gradually increased (Figure 17B). When we calculated the 
ratio of SNAT1 levels to GAD65 as an indicator of its expression at relevant inhibitory 
synapses, SNAT1 levels actually decreased approximately 25-fold during postnatal 
maturation (Figure 17B).  We also examined the expression profile of two additional 
transporters involved in synaptic GABA metabolism: the excitatory amino acid 
transporter, EAAT3 (see Figure 15A), and the GABA reuptake transporter, GAT-1, to 
determine if SNAT1 expression is uniquely regulated during development.  The relative 
expression ratio for each transporter displayed a different temporal pattern (Figure 17D), 
supporting a highly specific age-dependent regulation of SNAT1 expression by inhibitory 
neurons.  
 These findings demonstrate that SNAT1 in the hippocampus is expressed 
selectively by interneurons and that the 25-fold decrease in amount of SNAT1 expressed 
at developing inhibitory synapses highly correlates with the age-dependent loss of 
System A’s constitutive contribution of glutamine to synaptic GABA.  SNAT2’s 
developmental expression profile was contrary to the observed physiological effects.  
Therefore, our findings support that SNAT1, not SNAT2, likely functions as the 
transporter mediating glutamine uptake for synaptic GABA in hippocampus and thus we 
focused protein expression changes in subsequent studies on SNAT1.  
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Figure 17.  SNAT1 is selectively expressed by interneurons in hippocampal area 
CA1 and SNAT1 expression gradually decreases in an age-dependent manner 
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Figure 17.  SNAT1 is selectively expressed by interneurons in hippocampal area 
CA1 and the SNAT1 expression gradually decreases in an age-dependent manner 
Ai-ii, Non-pyramidal cell bodies localized in stratum oriens (st. oriens), st. radiatum (st. 
rad.) and bordering stratum pyramidale (st. pyr.) in both immature (Ai) and mature (Aii) 
hippocampus positively express SNAT1.  Scale bar represents 20µm.  B, D, 
Representative western blots illustrating amount of SNAT1, GAD65, EAAT3, and GAT-
1 expressed in whole hippocampal lysates from sequential postnatal ages and adulthood.  
Actin was used as a loading control.  Bar graphs compare relative expression levels of the 
various transporters in panels B and D after normalization to GAD65 (n=3).  C, 
Representative western blot illustrating amount of SNAT2 protein expressed in immature 
and adult hippocampus.  Bar graph compares SNAT2 protein levels after normalization 
to actin (n=3).  B-D, The position of protein standards is shown on the left.  Error bars, 
SEM. 
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We hypothesized that the physiologically relevant pool of System A transporters 
would be enriched in the synaptosomal fraction, and that age-dependent changes in 
SNAT1 protein would be even more pronounced in this fraction than in whole lysates.  
Consistent with this hypothesis, immature synaptosomes expressed an increased amount 
of SNAT1 protein relative to mature synaptosomes (p<0.01, n=3; Figure 18A,B).  In 
addition, the proportional difference in amount of SNAT1 protein (raw signal) expressed 
between immature and mature hippocampus was magnified in the synaptosomal fraction 
(2.7 ± 0.6 fold higher) compared with the whole lysate (1.8 ± 0.4 fold higher; data not 
shown).  To further investigate whether SNAT1 basal uptake activity correlated with its 
protein levels, we measured uptake of [3H]MeAIB in immature and mature hippocampal 
synaptosomes.  After a 2.5 minute incubation, basal [3H]MeAIB uptake was almost four-
fold higher in immature compared with mature synaptosomes (p<0.05, n=3; Figure 18C) 
and this difference was conserved with both 5 and 10 minute incubations of [3H]MeAIB 
(data not shown).  Although MeAIB is a substrate for both SNAT1 and SNAT2, the 
developmental decrease in SNAT1 protein expression in synaptosomes is reflected in a 
parallel reduction in MeAIB uptake, and therefore interneuron terminals likely selectively 
reduce SNAT1 uptake activity in an age-dependent manner.  Therefore, we conclude that 
SNAT1 protein expression and, even more so, its surface activity at inhibitory synapses is 
developmentally regulated and likely governs the age-dependence of System A’s 
constitutive contribution to synaptic GABA. 
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Figure 18.  Reduced SNAT1 surface activity at mature inhibitory synapses mediates 
age-dependent loss of glutamine’s constitutive contribution to synaptic GABA 
A, Representative western blots illustrating amount of SNAT1 and GAD65 protein 
expressed in immature and mature hippocampal synaptosomes.  The position of protein 
standards is shown on the left.  Actin served as a loading control.  B, Comparison of the 
relative amount of SNAT1 expressed in panel A after normalization to GAD65 levels 
(n=3), **p<0.01.  C, Comparison of MeAIB uptake reported as fmol/mg protein between 
immature and mature hippocampal synaptosomes (n=3), *p<0.05.  B-C, Error bars, SEM. 
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SNAT1 surface activity is the only age-dependent change governing the changing 
contribution of glutamine to vesicular GABA   
Thus far our results support that System A transporters serve both a constitutive 
and activity-dependent role in modulating vesicular GABA content and inhibitory 
synaptic strength.  These roles are governed by the uptake activity of System A 
transporters (although likely SNAT1, see Discussion), which are dynamically regulated 
by both developmental cues and synaptic depolarization.  Although glutamine uptake 
appears to be the key regulatory point in the glu-gln-GABA pathway at synapses, we 
considered that developmental structural changes in the hippocampus, particularly in the 
relationships between inhibitory synapses and astrocytic processes or excitatory synapses 
could also result in changes in substrate (glutamine or glutamate, respectively) 
availability (see Figure 15A).  To address this possibility, we examined if a decrease in 
glutamine supply upstream or a decrease in the contribution of new GABA synthesis to 
vesicular filling downstream of System A transporters could explain the age-dependent 
loss of System A’s constitutive contribution of glutamine to synaptic GABA. 
We first investigated potential changes in glutamine supply by examining the 
effect of exogenous L-glutamine on mIPSC amplitudes.  We confirmed our previous 
report that addition of exogenous L-glutamine (2mmol/L) had no effect on mIPSC 
amplitudes in immature hippocampal slices, arguing that endogenous extracellular 
glutamine levels already saturate System A transporters  ((Fricke et al. 2007), Figure 
19A, B).  Therefore, if endogenous extracellular glutamine were sufficiently reduced in 
mature hippocampus such that glutamine no longer constitutively contributed to synaptic 
GABA, then addition of exogenous L-glutamine should increase mIPSC amplitudes.  
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However, exogenous L-glutamine had no effect on mIPSC amplitudes in mature slices 
either (101 ± 5% of control, n=5, p=0.8; Figure 19A,B).  Next, we investigated if mature 
synaptic vesicles rely less on newly synthesized GABA for vesicle filling by comparing 
the effect of the GAD inhibitor, 3-mercaptoproprionic acid (3-MPA), on mIPSC 
amplitudes from immature and mature slices.  If newly synthesized GABA is not required 
for vesicle filling in mature neurons, inhibiting GAD should have no effect on mIPSC 
amplitudes.  However, 3-MPA (1mmol/L) reduced mIPSC amplitudes to a similar extent 
in immature and mature slices (Immature: 35 ± 9 pA, n=10 vs. 25 ± 7 pA after 3-MPA, 
p<0.05, n=7; Mature: 36 ± 5 pA, n=18 vs. 30 ± 5 pA after 3-MPA, p<0.05, n=5; student’s 
t-test, Figure 19C,D).  These results support that a decrease in System A-mediated 
glutamine uptake, and not other elements of the glu-gln-GABA pathway, mediates the 
age-dependent loss of System A’s constitutive contribution of glutamine to synaptic 
GABA.  
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Figure 19.  Developing inhibitory synapses do not down-regulate constitutive 
activity of the entire glu-gln-GABA cycle 
A, Representative average mIPSC waveforms in control (black) and after 5 min. in 
exogenous 2mM glutamine from immature and mature slices.  B, Comparison of the 
effect of 2mM exogenous glutamine reported as a percent control of baseline (n=5).  
Error bars, SEM.  C, Average representative mIPSC waveforms from control (black) 
neurons and neurons exposed to 1mM 3-MPA in immature and mature slices.  D, 
Comparison of mIPSC amplitudes in control (black) and in 1mM 3-MPA ACSF (see text 
for ‘n’) reported as average median mIPSC amplitudes.  *p<0.05; Error bars, SD.  A, C, 
Scale bars, 10pA and 20ms.   
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Discussion 
 
 Coupling between GABA synthesis and vesicle filling (Jin et al. 2003) provides a 
mechanism whereby supply of GABA’s metabolic precursors to inhibitory synapses may 
dynamically up- or down-regulate vesicular GABA content and quantal size.  Even 
though dynamic changes in vesicle content are a newly recognized form of synaptic 
plasticity (Edwards 2007), there are very few examples where this plasticity is observed 
under physiological conditions, and these examples have demonstrated that supply of 
glutamate by EAAT3 rapidly modulates inhibitory synaptic strength (Mathews & 
Diamond 2003, Stafford et al. 2009, Hartmann et al. 2008).  We now have demonstrated 
that the surface activity of System A transporters, governing glutamine uptake at 
inhibitory synapses, is acutely regulated to modulate quantal size, providing the first 
example of such regulation of a substrate transporter dynamically shaping fast 
neurotransmission.  We also have demonstrated that the constitutive contribution of 
System A-mediated glutamine uptake to synaptic GABA is determined by a 
developmentally regulated change in the surface activity of these transporters, paralleling 
a maturational change in the role of GABA in the hippocampus.   
We showed previously that uptake of exogenous (Mathews & Diamond 2003) or 
synaptically released (Stafford et al. 2009) glutamate by EAAT3 enhances quantal release 
of synaptic GABA (see Figure 15A).   However, because astrocytes maintain very low 
extracellular glutamate levels, this metabolic pathway may only contribute to synaptic 
GABA under conditions in which extracellular glutamate overwhelms astrocytic 
glutamate transporters.  In contrast, extracellular glutamine exists at high levels and there 
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should be a continuous supply available to inhibitory synapses.  Moreover, astrocytic 
processes expressing SNAT3 or SNAT5, the System N transporters capable of mediating 
glutamine efflux (Figure 15A), ensheath GABAergic axon terminals (Boulland et al. 
2002, Cubelos et al. 2005) suggesting that glutamine may be locally maintained at higher 
levels than measured in the cerebrospinal fluid.  Of the two independent substrate supply 
pathways (EAAT3 and System A), the System A pathway appears to be regulated 
intrinsically, by regulation of transporter activity rather than substrate availability, it is 
likely to play a unique role in homeostatic plasticity of inhibitory synapses.  
 
SNAT1 is a key regulator of GABA metabolism at inhibitory synaptic terminals 
 Although both System A transporters, SNAT1 and SNAT2, have been viewed 
traditionally as potential suppliers of glutamine for synaptic glutamate and GABA 
(Chaudhry et al. 2002, Bak et al. 2006), recent immunohistochemical studies support that 
these two transporters have distinct and non-overlapping expression patterns in the 
hippocampus.  SNAT2 is selectively expressed by excitatory neurons in adult 
hippocampus (Jenstad et al. 2009, Gonzalez-Gonzalez et al. 2005), and does not appear 
to play a significant role in neurotransmitter glutamate metabolism (Kam & Nicoll 2007, 
Grewal et al. 2009).  In contrast, our immunohistochemical findings are supported by a 
recent study demonstrating SNAT1 protein expression limited to GAD67-expressing 
neurons in area CA1 (Solbu et al.).  This study also demonstrated co-localization of 
SNAT1 protein with the vesicular GABA transporter (vGAT), a marker for GABAergic 
presynaptic terminals, at axon varicosities in cortical interneuron-enriched cultures.  
Moreover, in our study, SNAT2 protein actually increased with age (Figure 17), opposite 
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to the electrophysiological and biochemical studies showing a maturational loss in 
System A’s constitutive contribution of glutamine to synaptic GABA (Figure 16).  
Although we did not rule out a role for SNAT2 in neurotransmitter GABA metabolism, 
we have provided multiple lines of evidence implicating SNAT1.  Therefore, although 
the synaptic localization of SNAT1 has been controversial previously (Melone et al. 
2004, Conti & Melone 2006), our current study and that of Solbu et al. strongly support 
the conclusion that SNAT1 functions at or near inhibitory synaptic terminals to supply 
glutamine for neurotransmitter synthesis. 
  
Activity-dependent regulation of System A surface activity modulates vesicular GABA 
content 
 Our study is the first to demonstrate dynamic modulation of inhibitory synaptic 
strength via regulation of the surface activity of a presynaptic substrate transporter.  
Because our findings show that extracellular glutamine levels are sufficient to saturate 
System A transporters, altering glutamine supply to inhibitory synapses requires up- or 
down-regulation of their surface activity.  Previous studies in mature animals were able to 
demonstrate a requirement for glutamine to maintain neurotransmitter pools only during 
periods of increased metabolic demand (Bryant et al. 2009, Liang et al. 2006, Tani et al. 
2007).  Whether specific elements involved in the cycling of glutamine between 
astrocytes and neurons can be up-regulated had not been previously explored.  However, 
our results show that inhibitory neurons adapt to an increase in metabolic demand by 
increasing System A surface activity, offering a mechanism to mediate this increase in 
glutamine contribution to the GABA neurotransmitter pool.  In fact, our results are 
113 
consistent with a previous study examining activity-dependent changes in glu-gln-GABA 
cycling (Liang et al. 2006) and may explain the underlying mechanism for these changes. 
 Several studies have demonstrated that hyperexcitability and acute seizure-like 
activity can be induced in hippocampal slices by elevating extracellular potassium 
(Dzhala & Staley 2003, Jensen & Yaari 1997, Traynelis & Dingledine 1988).  We 
induced a more moderate level of hyperexcitability with the goal of depolarizing neurons, 
increasing synaptic activity and creating a higher demand for GABA.  After 30 minutes, 
quantal size at GABAergic synapses was transiently increased.  Interestingly, the increase 
in quantal size was delayed, appearing within 10 minutes after the depolarization 
protocol.  There are two possible explanations for this finding:  One explanation is that 
although System A surface activity is increased during the period of hyperexcitability, 
other factors explain why quantal size does not increase until after membrane potential or 
level of synaptic activity returns to normal.  For example, System A activity could 
increase to maintain GABA synthesis and vesicular filling during the hyperexcitable 
state, compensating for increased demand.  When synaptic activity is halted abruptly by 
addition of tetrodotoxin, the higher rate of GABA synthesis and slower rate of vesicular 
release may result in an “overfilling” of vesicles.  Alternatively, elevated K+ could impair 
the function of System A transporters due to reduction of the electrochemical gradient 
driving glutamine uptake such that an increase in glutamine uptake occurs only when a 
normal gradient is restored.  The second explanation is that there is a delay in the 
upregulation in System A surface activity in response to depolarization.  For example, it 
may take minutes for biochemical signals to translate into increased surface activity, 
although the precise mechanism of transporter regulation and the signals involved have 
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not been determined.  Our synaptosomal uptake assays do not help differentiate between 
the two possible explanations for the delay.  In the immature synaptosomes, System A 
function was increased immediately following depolarization, whereas in the mature 
synaptosomes, the increase was observed after a delay.  Therefore, it remains a possibility 
that different mechanisms are involved in the activity-dependent role of System A 
transporters at different ages. 
 Although we have not determined the precise mechanism by which the surface 
activity of System A transporters is regulated, we have demonstrated that depolarization 
of synaptosomal membranes is sufficient to upregulate System A surface activity and 
therefore can account for the changes we observed in whole hippocampal slices.  The 
mechanism may involve either regulation of System A’s catalytic efficiency or 
translocation of transporters to the surface, or both.  Dual modes of transporter regulation 
involving both surface expression and catalytic activity are common, as previous studies 
have identified independent mechanisms that regulate EAAT3 (Gonzalez et al. 2002), 
GLUT4 (Somwar et al. 2001), and NET (Apparsundaram et al. 2001) activity.  Both the 
mechanism and the specific signaling molecules that regulate System A surface activity 
need to be resolved.  Moreover, developmental differences in the regulation of System A 
transport activity may explain why its surface activity increases more rapidly in immature 
than mature synaptosomes after high K+-induced depolarization (Figure 15C,D).  We 
propose that the acute regulation of System A transport is an intrinsic homeostatic 
mechanism to link metabolic demand with substrate supply.  Likewise, discovery of this 
important role of System A transporters suggests that future studies could explore its 
function in disorders characterized by chronic hyperexcitability such as epilepsy. 
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Implications of altered System A surface activity during hippocampal maturation 
 We considered alternative mechanisms that might explain the age-dependent loss 
in glutamine’s constitutive contribution to synaptic GABA.  We first considered that the 
degree of saturation of GABAA receptors might increase during development.  For 
example, if the synaptic [GABA]cleft or the GABAA receptor affinity for GABA were 
increased during postnatal maturation, modest changes in vesicular GABA content might 
have little or no consequence on the inhibitory postsynaptic response.  Several findings 
argue against this explanation.  First, we demonstrated that similar concentrations of the 
low affinity antagonist TPMPA reduced mIPSC amplitudes equivalently in immature and 
mature slices (Figure 14E).  In fact, slightly less TPMPA was required to block mature 
mIPSCs suggesting a lower degree of GABAA receptor saturation.  Second, high K+-
induced depolarization increased synaptic [GABA]cleft and thus mIPSC amplitudes by a 
similar extent at both ages (Figures 14-15), indicating that a single vesicle does not 
saturate post-synaptic receptors at either age.  Lastly, previous studies indicated that 
affinity of synaptic GABAA receptors is reduced during maturation (Laurie et al. 1992, 
Bohme et al. 2004).  We did consider the additional explanation that glutamine’s 
constitutive contribution to synaptic GABA at mature synapses is slower, requiring 
hours, not minutes, to observe changes, similar to observations in glutamatergic neurons 
(Kam & Nicoll 2007).  If this were true, it still would suggest a developmental change in 
the metabolic pool of precursor for GABA synthesis that disconnects System A 
transporters from the rapidly and dynamically modulated neurotransmitter pool measured 
in our experiments.  Therefore, we conclude that SNAT1 protein expression and 
consequentially its surface activity at inhibitory synapses is developmentally regulated 
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and directly mediates the age-dependent loss in System A’s constitutive contribution of 
glutamine to synaptic GABA.  
Why would developing inhibitory neurons scale down the constitutive surface 
activity of System A transporters but maintain an intrinsic mechanism to increase its 
surface activity upon synaptic depolarization?  During early postnatal development, 
GABA coordinates excitatory synapse maturation and therefore early inhibitory synapses 
likely encounter little extracellular glutamate supply.  We hypothesize System A’s 
constitutive surface activity possibly functions to sustain synaptic GABA during this 
period and thus System A function may be critical during hippocampal maturation.  After 
a sufficient density of excitatory synapses form, GABA metabolism may be additionally 
modulated by EAAT3-dependent glutamate uptake.  Still, neurons maintain the intrinsic 
mechanism for System A transporters to modulate GABA synthesis during periods of 
increased excitability.  In summary, our results demonstrate that regulation of System A 
surface activity is a novel mechanism linking metabolic demands for GABA to its 
vesicular packaging, adapting inhibitory neurotransmission to a range of activity states. 
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CHAPTER IV 
 
CONCLUSIONS, DISCUSSION AND OUTSTANDING QUESTIONS 
 
GABA functions as the primary inhibitory neurotransmitter in the mammalian 
brain.  In hippocampus, GABA serves multiple roles during development and throughout 
adulthood, which include to: 1) orchestrate synapse maturation and synaptogenesis, 2) 
maintain inhibitory synaptic transmission, and 3) regulate the excitability and 
synchronize the neuronal output of principal neurons.  Because normal brain function 
requires intact inhibitory synaptic transmission, interneurons must possess mechanisms to 
adapt synaptic GABA during a wide range of activity states.  I hypothesized that one 
effective mechanism may involve regulating GABA synthesis and vesicular GABA 
content through modulating the supply of glutamine by System A glutamine transporters.  
In addition, because GABA serves critical roles during early hippocampal development, I 
hypothesized that the role of System A transporters at inhibitory synapses also may be 
developmentlally regulated. Therefore, this dissertation explored the role for System A 
transporters in regulating inhibitory synaptic transmission.  In addition, I asked if 
modulation of System A surface activity dynamically regulated GABA synthesis in 
response to changing developmental and neuronal activity states.  I now conclude that 
astrocytes supply interneuron terminals with glutamine for neuronal uptake by System A 
transporters, where supply of glutamine exists in a dynamic equilibrium with GABA 
synthesis and vesicle filling.  I also conclude that System A transporters serve both a 
constitutive and activity-dependent role in modulating vesicular GABA content and 
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inhibitory synaptic strength.  I demonstrated that synaptic depolarization up-regulates the 
surface activity of System A transporters and thus induces an increase in vesicular GABA 
content in both immature and mature hippocampus.  However, because System A’s basal 
uptake activity and therefore its constitutive contribution to vesicular GABA content 
diminished over the first two postnatal weeks, its role in mature hippocampus is only 
manifested in an activity-dependent manner.  Furthermore, my results support that these 
constitutive and activity-dependent roles are likely mediated by the SNAT1 subtype of 
System A transporters.  Therefore, my findings strongly support that the surface activity 
of SNAT1, regulated both by depolarization and by developmental cues, is the key 
component in a novel mechanism to dynamically link metabolic demand for GABA with 
vesicular GABA content and inhibitory synaptic strength.  This body of research provides 
a framework for future studies to explore the implications of SNAT1’s constitutive and 
activity-dependent roles in hippocampal synapse maturation, as well as in disorders 
characterized by chronic hyperexcitability such as epilepsy.   
In this final chapter, I will provide a rationale for these conclusions, as well as 
discuss their physiological implications for the field.  Interwoven in each section are 
unresolved questions that stemmed from this thesis research as well as potential future 
experiments to address these questions. 
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SNAT1 defines System A transport at interneuron terminals 
 
Unique functional roles for SNAT1 and SNAT2 
Multiples lines of evidence now support that SNAT1 is likely the main System A 
transporter that participates in the glu-gln-GABA pathway at interneuron terminals.  
First, we observed immunoreactivity for SNAT1 in only non-pyramidal neurons in area 
CA1 of hippocampus (Figure 17), suggesting a unique role for SNAT1 on interneurons.  
This expression pattern is not developmentally regulated, as it occurred in both immature 
(P8) and mature (P25) hippocampus.  Second, preliminary data from our lab 
demonstrates that SNAT1 immunoreactivity positively co-localizes with GABA in P21 
hippocampus (data not shown).  Future studies should confirm this preliminary result and 
repeat this experiment in hippocampal sections from sequential postnatal ages.  Lastly, in 
Chapter III, I demonstrated that the level of SNAT1 expression in hippocampal 
synaptosomes correlated with the measured uptake of [3H]MeAIB (Figure 18) and with 
the physiological data that implicated a loss in System A’s constitutive contribution to 
synaptic GABA (Figure 16).  This correlation was not observed for SNAT2, as protein 
levels in immature whole hippocampal lysates were faint and increased to a low level in 
mature lysates.   
 It is now apparent that glutamatergic and GABAergic neurons likely evolved 
unique yet similar mechanisms to regulate synthesis of their neurotransmitters through 
selective expression of System A transporters.  Indeed, recent immunohistochemical 
studies identified that glutamatergic neurons across multiple brain structures selectively 
express SNAT2 (Gonzalez-Gonzalez et al. 2005, Jenstad et al. 2009).  Therefore, 
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previous studies in Chapter I that identified a MeAIB-sensitive role for glutamine in 
excitatory neurotransmission were likely studying glutamine transport by SNAT2.  
Future studies should investigate if glutamatergic neurons only require glutamine under 
pathological conditions (see Chapter I) and if glutamatergic neurons possible regulate 
SNAT2 surface activity to mediate this requirement. 
 
Several interneuron subtypes express SNAT1 
An outstanding question in the field remains that if interneurons selectively 
express SNAT1, is SNAT1 ubiquitously or selectively expressed amongst interneuron 
subtypes?  Electrophysiological and preliminary immunohistochemical data indicates that 
in hippocampal area CA1, several interneuron subtypes that make axo-somatic and axo-
dendritic synapses express SNAT1.  In an effort to categorize the interneuron subtypes 
that express SNAT1, our lab completed co-localization experiments between SNAT1 and 
several neurochemical markers of interneurons, including parvalbumin (PV), 
somatostatin (SOM), and calbindin (CB) in P8 and P25 hippocampus (n=2 tissue 
sections/marker/age).  At the resolution of neuronal cell bodies, a fraction of SNAT1+ 
cell bodies were also PV+ in P8 hippocampus (data not shown).  Therefore, one sub-
population appears to be PV+ basket cells, where their cell bodies localize near the 
pyramidale cell layer and their axons exclusively innervate the perisomatic region of CA1 
pyramidal neurons.  However, not all SNAT1+ neurons are PV+, indicating that more 
than one interneuron subtype expresses SNAT1.  Data presented in Chapters II and III 
support that SNAT1 functions at interneuron terminals.  Consequently, future 
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experiments must utilize techniques capable of resolving SNAT1 immunoreactivity at 
synaptic terminals, such as confocal microscopy.   
Lastly, our electrophysiological data supports that several interneuron subtypes 
likely express SNAT1.  Using the data presented in Figure 16, we assumed that 
subpopulations of synapses have similar quantal sizes and thus we grouped mIPSC 
amplitudes into quartiles.  For example, axo-dendritic synapses may elicit smaller mIPSC 
amplitudes (quartiles 1 and 2) while axo-somatic synapses may elicit larger mIPSC 
amplitudes (quartiles 3 and 4) (Figure 20).  I found that MeAIB uniformly reduced 
mIPSC amplitudes in each quartile in immature slices (P7-8; p<0.05 in each quartile), 
supporting that multiple interneuron subtypes express SNAT1.  MeAIB does not reduce 
mIPSC amplitudes in any quartile in mature slices (P22-25; p>0.05 in each quartile).  
However, a noticeable pattern in Figure 19 resembles a shift towards MeAIB reducing 
the largest mIPSC amplitudes as development progresses.  Although current data 
supports that a uniform loss in System A’s constitutive contribution to synaptic GABA 
likely occurs at several subtypes of mature interneuron synapses, it will be important for 
future anatomical studies to confirm this conclusion. 
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Figure 20.  Effect of MeAIB on mIPSC amplitudes binned into quartiles throughout 
postnatal development 
Comparison of the effect of 10mM MeAIB on mIPSC amplitudes reported as a % change 
from baseline and binned into quartiles from P7-P8 (black), P10-P12 (dark gray), or P22-
25 (light gray) hippocampal slices.  Error bars, SEM. 
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SNAT1 transports astrocytic glutamine for vesicular GABA synthesis 
 
Data in both Chapters II and III support the conclusion that when active, SNAT1 
functions within an independent substrate pathway that supplies glutamine to inhibitory 
terminals to maintain or to increase vesicular GABA synthesis.  This pathway involves 
the metabolic and transport processes illustrated in Figure 21, and possibly represents 
only a subset of processes that enable glutamine to contribute to GABA synthesis as 
discussed below. 
 
Role of EAAT2 and System N transporters 
Studies in Chapter II demonstrated that EAAT2-mediated glutamate uptake by 
astrocytes provides one source of substrate for glutamine synthetase to synthesize 
glutamine (Figure 12).  In addition, compensatory synthesis of astrocytic glutamate by 
glucose or GABA catabolism did not prevent DHK (a selective EAAT2 inhibitor) from 
eliminating the effect of MeAIB during resting conditions (see Figures 12 and 21).  
However, this does not eliminate the possibility that these pathways may contribute to 
astrocytic glutamate synthesis under conditions of increased synaptic activity.  Therefore, 
future experiments could explore if inhibiting glucose or GABA catabolism eliminates 
the effect of MeAIB on mIPSC amplitudes following periods of increased neuronal 
activity.   
Although EAAT2 clears synaptically released glutamate, astrocytic processes that 
express System N transporters ensheath inhibitory terminals both proximal and distal to 
glutamatergic terminals in area CA1 (Boulland et al. 2002, Cubelos et al. 2005).  This 
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anatomical arrangement provides inhibitory terminals with a ubiquitous supply of 
glutamine and thus facilitates SNAT1 to regulate GABA synthesis across several 
interneuron subtypes.  Moreover, this ubiquitous glutamine supply exists at 
concentrations capable of saturating SNAT1 and does not limit the constitutive 
contribution of glutamine to synaptic GABA (Figure 19). 
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Role of GLS1 
 As noted previously, the role of GLS1 as the primary neuronal enzyme 
synthesizing glutamate from glutamine at inhibitory terminals remains controversial.  
Upon identifying an age-dependent reduction in the constitutive contribution of SNAT1-
mediated glutamine uptake to synaptic GABA, I asked two questions regarding the role 
of GLS1: 1) Is GLS1 the enzyme that synthesizes neuronal glutamate from glutamine 
supplied by SNAT1? and 2) Is GLS1’s potential role in vesicular GABA synthesis 
developmentally regulated?  To address these questions, I examined the effect of 6-diazo-
5-oxo-L-norleucine or DON, a glutaminase inhibitor, on mIPSC amplitudes in immature 
and mature hippocampal slices (using identical recording conditions to that reported in 
Chapter III).  Unexpectedly, DON [6mM, 30m-1h incubation; (Sepkuty et al. 2002, 
Holten & Gundersen 2008)] did not reduce mIPSC amplitudes from immature slices (40 
± 10pA, n=23, v. 37 ± 9pA after DON, n=10; p=0.4, un-paired t-test).  However, in 
mature slices, DON did slightly reduce mIPSC amplitudes (36 ± 5pA, n=14, v. 31 ± 5pA 
after DON, n=9; p<0.05, un-paired t-test) with no effect on mIPSC decay or frequency.   
DON is a non-selective glutaminase inhibitor, and thus future experiments should 
first validate these results with a selective pharmacological inhibitor.  If these results are 
reproducible, two possible explanations exist: First, at immature hippocampal inhibitory 
terminals, an enzyme besides GLS1 converts glutamine supplied by SNAT1 to glutamate.  
This may exist as an orphan glutaminase isozyme insensitive to DON (see Chapter I) or 
as an entirely different enzyme capable of deamidation through either single or multiple 
catalytic steps.  Future electrophysiological experiments could explore the contribution of 
candidate enzymes through applying selective pharmacological inhibitors.  Second, at 
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mature terminals, a source besides SNAT1 possibly supplies glutamine to serve as a 
substrate for GLS1.  Amino acid Systems L, ASC, N, and A transport the majority of 
glutamine in the brain.  Hippocampal astrocytes selectively express System N 
transporters, leaving members of Systems L and ASC, or an unidentified glutamine 
transporter, as candidates.  A recent immunohistochemical study in hippocampus of adult 
mice co-localized ASCT2 with MAP2 but not NeuN, supporting a dendritic but not 
somatic neuronal localization (Gliddon et al. 2009).  Although expression by interneuron 
terminals remains unknown, glutamine is a substrate for amino acid exchange by ASCT2 
(Bak et al. 2006).  ASCT2-sensitive transport is defined as glutamine transport insensitive 
to MeAIB and BCH (a selective substrate for System L).  Future studies could explore 
the role of ASCT2 in GABA synthesis through two experiments: 1) Determine if 
neuronal terminals possess functional ASCT2 transport activity by measuring 
[3H]glutamine uptake that is insensitive to MeAIB and BCH in hippocampal 
synaptosomes and 2) Examine the contribution of glutamine supplied by ASCT2 to 
vesicular GABA synthesis by recording the effect of MeAIB + BCH on mIPSC 
amplitudes.   
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Supply of GABAergic precursors dynamically regulates vesicular GABA content 
 
 Multiple factors determine the concentration of neurotransmitter in a synaptic 
vesicle, including the cytosolic concentration of neurotransmitter, the activity of the 
vesicular transporter, and the proton electrochemical driving force.  Studies presented in 
Chapters II and III support the conclusion that at hippocampal interneuron terminals, the 
cytosolic concentration of GABA is an important determinant of vesicular GABA 
content.  Moreover, I conclude that a dynamic equilibrium exists between the supply of 
GABAergic precursors and the cytosolic concentrations of newly synthesized GABA.  
Blocking glutamine transported by active SNAT1 robustly and rapidly decreased 
vesicular GABA synthesis within 5 minutes of MeAIB application under a variety of 
neuronal conditions (Figures 6-9, 14-15).  This implies that glutamine supplied by 
SNAT1 must be in equilibrium with glutamate and GABA synthesis downstream.  
Because GAD65 and vGAT exist as part of a protein complex at synaptic vesicles, this 
suggests that the equilibrium between supply of precursors with the cytosolic GABA 
concentration likely extends to vesicle filling.   
The existence of an equilibrium between glutamine supply, GABA synthesis, and 
vesicle filling yields several conclusions and avenues for future experiments:  First, 
interneurons must be equipped with mechanisms to refill synaptic vesicles with GABA in 
order to avoid depletion of vesicular stores during their high rates of neuronal firing.  Up-
regulation of SNAT1’s surface activity increases glutamine supply and thus increases 
cytosolic GABA concentrations, thereby providing one possible mechanism to sustain 
vesicle filling during periods of increased metabolic demands.  
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Second, because electrophysiological experiments examining changes in vesicular 
GABA content took place in the absence of synaptic activity, results from these studies 
suggest that vesicles do not have to be released and recycled before an effect of 
modulating GABA synthesis on vesicle filling is observed.  This suggests that when 
active, glutamine supplied by SNAT1 and glutamate supplied by EAAT3 (Mathews & 
Diamond 2003, Stafford et al. 2009) modulate the concentration of vesicular GABA in 
synaptic vesicles ready to be released.  These vesicles comprise the “readily releasable 
pool” (RRP) and their release can be evoked through application of a hyperosmotic 
solution.  In Chapter II, I demonstrated that MeAIB reduced hyperosmotically-evoked 
mIPSC amplitudes by a similar magnitude as TTX-sensitive mIPSCs.  In addition, 
previous studies demonstrate that synaptic vesicles released spontaneously and during 
neuronal activity belong to the same vesicle pool (Groemer & Klingauf 2007) and utilize 
similar modes of endocytotic uptake (Ryan et al. 1997).  Therefore, these findings 
support that the dependence on glutamine supply for vesicular GABA synthesis applies to 
a physiologically relevant pool of vesicles released following an action potential.    
Third, in Chapter III, I demonstrated that at immature interneuron terminals, 
glutamine supplied by SNAT1 can bi-directionally regulate vesicular GABA content 
(Figures 14, 15).  This result implies that terminals can release both “under- and over-
filled” synaptic vesicles.  The cellular mechanisms that influence the extent of vesicle 
filling with synaptic function at central synapses remain unresolved.  However, these 
studies support that under the neuronal activity states examined, GABAergic vesicles are 
not filled to static “set-points” of neurotransmitter.  Instead, vesicular GABA content 
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fluctuates across a range of concentrations and thus is a key determinant of synaptic 
[GABA]cleft and inhibitory synaptic strength.   
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Activity-dependent regulation of SNAT1 surface activity 
 
 Mechanisms of synaptic plasticity modulate synaptic strength and facilitate 
information processing.  Presynaptic control of quantal size has gained recent attention as 
a possible mechanism of synaptic plasticity (Edwards 2007).  In Chapter III, I 
demonstrated that a moderate level of hyperexcitability upregulated SNAT1 surface 
activity to enhance vesicular GABA content and presynaptic quantal size.  Whether other 
patterns of neuronal activity upregulate SNAT1 surface activity have not been explored.  
However, augmenting vesicular GABA content will only increase inhibitory synaptic 
strength if postsynaptic receptors remain unsaturated by synaptic GABA.  For example, 
high frequency stimulation protocols that induce LTP presynaptically are commonly 
associated with a persistent activity-dependent increase in vesicle release probability.  
This may result in terminals releasing more than one synaptic vesicle and thus under 
these conditions, synaptic GABA may saturate postsynaptic GABAA receptors.  
Similarly, distinct patterns of neuronal activity may modulate the number of GABAA 
receptors expressed at the cell surface to alter their degree of saturation by synaptic 
GABA.   
Therefore, I hypothesize that the functional implications for the activity-
dependent role of SNAT1 will depend upon the degree of GABAA receptor saturation and 
are thus two-fold: 1) During periods of interneuron firing that result in the saturation of 
GABAA receptors by synaptic GABA, interneurons may continue to upregulate SNAT1 
surface activity as a mechanism to maintain vesicular GABA content and thus the 
neurotransmitter pool of GABA.  2) During periods of interneuron firing that maintain 
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unsaturating conditions for GABAA receptors, upregulation of SNAT1 surface activity 
provides interneurons with a gain control mechanism to fine-tune GABA synthesis, 
vesicular GABA content, and inhibitory synaptic strength.  Given the extensive axonal 
arbors of interneurons, small adjustments in their presynaptic input could still have a 
large impact on the excitability and neuronal output of principal neurons.  Therefore, 
under relevant neuronal activity states, modulation of SNAT1 surface activity indeed 
defines one presynaptic mechanism that influences quantal size and thus joins existing 
mechanisms of synaptic plasticity that dynamically regulate synaptic strength. 
 
From studies presented in Chapter III, I hypothesize that one cellular mechanism 
that models the activity-dependent increase in SNAT1-mediated glutamine uptake at both 
immature and mature inhibitory terminals includes the following processes (Figure 22):  
1) Immature interneuron terminals express an increased amount of active SNAT1 protein 
relative to mature interneuron terminals, allowing SNAT1’s constitutive surface activity 
to maintain ongoing GABA synthesis and inhibitory synaptic transmission (Figures 8,16).  
Synaptic depolarization may activate cellular signals to enhance glutamine’s KM for 
existing SNAT1 transporters at the cell surface and thus allow for an immediate increase 
in SNAT1 uptake upon restoring the electrochemical gradient for glutamine uptake 
(Figure 15).  The upregulation of SNAT1’s uptake activity increases glutamine supply, 
vesicular GABA content, and inhibitory synaptic transmission.  2) By the end of the 
second postnatal week, the amount of SNAT1 protein expressed in hippocampus reduces 
to adult levels.  This leads to the question, “What is the cellular localization of SNAT1 
protein in mature hippocampus and why is SNAT1 constitutively inactive?”  One 
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hypothesized mechanism involves activation of a cellular signal towards the end of the 
second postnatal week that redistributes SNAT1 protein to an endsome-containing 
intracellular compartment.  If true, synaptic depolarization likely activates cellular signals 
to redistribute SNAT1 at the plasma membrane surface, thereby upregulating SNAT1 
uptake activity (increase in glutamine’s VMAX for SNAT1) to increase glutamine supply, 
GABA synthesis and inhibitory synaptic transmission.  Although this process likely 
occurs during synaptic depolarization, it appears that the increase in SNAT1 uptake 
activity is delayed upon restoring the electrochemical gradient (Figure 15). 
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Figure 22.  Age- and activity-dependent regulation of SNAT1 surface activity  
A cartoon that illustrates one possible mechanism that underlies the constitutive and 
activity-dependent roles for SNAT1 at inhibitory terminals.  Constitutive Role, In 
immature hippocampus, SNAT1 constitutively supplies inhibitory terminals with 
glutamine to maintain ongoing GABA synthesis.  As development progresses, mature 
hippocampal interneurons reduce the amount of SNAT1 protein expressed.  This turns off 
glutamine’s constitutive contribution to GABA synthesis, possibly due to endocytosis of 
SNAT1 transporters at the cell surface.  Activity-dependent Role, In immature 
hippocampus, synaptic depolarization enhances glutamine’s KM for existing SNAT1 
transporters at the cell surface, thereby increasing glutamine supply and vesicular GABA 
content.  If SNAT1 is localized within intracellular endosomes in mature interneurons, 
synaptic depolarization likely enhances glutamine’s VMAX for SNAT1 due to a 
trafficking-dependent mechanism.  This process would increase glutamine supply and 
vesicular GABA content.   
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To test these hypothesized mechanisms, I propose addressing the questions and 
experiments below using the following model systems.  Studies involving mature 
hippocampus could use slices or synaptosomes from hippocampi transduced with a 
recombinant adeno-associated viral vector that drives expression of SNAT1 or SNAT2 
under the control of the GAD promoter (AAV-GAD-SNAT) (paired hippocampi used as 
control).  SNAT1 antisense-transduced rats offer an additional tool to confirm its role in 
current physiological results, as well as to confirm its role in experiments proposed 
below.  SNAT2 antisense-transduced rats offer a tool to selectively probe SNAT1 
function with MeAIB for both future electrophysiology and uptake experiments.  
Unfortunately, transducing hippocampi with AAV constructs is not feasible in immature 
rats, as experiments cannot be complete until several weeks post-transduction.  Therefore, 
one possibility includes applying an RNA interference approach to knockdown SNAT1 
or SNAT2 expression using in utero electroporation (Wang & Kriegstein 2008).  An 
alternative approach involves designing selective inhibitors for both SNAT1 and SNAT2, 
a critical tool for the field independent of the studies proposed below.   
 
1) Does the high K+-induced depolarization alter glutamine’s KM or VMAX for SNAT1? 
Because MeAIB is a substrate for both SNAT1 and SNAT2, I propose future 
studies complete the saturation kinetic analysis for SNAT1 transport ± 10mM KCl in 
hippocampal synaptosomes from rats that express a reduced amount of SNAT2 protein, 
allowing [3H]MeAIB uptake to mostly reflect SNAT1 uptake activity.  According to the 
model in Figure 22, I hypothesize that the high K+-induced depolarization will reduce the 
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KM of glutamine for SNAT1 in immature synaptosomes and increase its VMAX in mature 
synaptosomes. 
 
2) Does the high K+-induced depolarization increase the surface expression of SNAT1? 
Prior to completion of the uptake assays, I attempted to measure the amount of 
SNAT1 expressed at the cell surface ± 10mM KCl using a surface biotinylation approach 
in hippocampal slices.  I could not detect a measurable SNAT1 protein band in the 
surface fraction even after exposure to 10mM KCl.  However, I have recently identified a 
few steps in my current protocol that can be optimized, as well as redesigned the steps 
involving slice incubation in 10mM KCl based upon results from the uptake assays.  
Therefore, future experiments should re-visit this approach.  According to the model in 
Figure 22, I hypothesize that the high K+-induced depolarization will increase the amount 
of SNAT1 protein expressed in the surface fraction of mature slices.  Moreover, 
comparing the distribution of SNAT1 protein between the intracellular and surface 
fractions from immature v. mature sham-treated slices will also test the hypothesis that 
SNAT1 protein localizes to an intracellular compartment in the absence of neuronal 
activity in mature hippocampus. 
 
3) Does the high K+-induced depolarization augment SNAT1-mediated currents? 
Transport of glutamine by SNAT1 requires co-transport of sodium, thereby 
producing an inward current upon uptake of substrate.  Because MeAIB is a selective 
substrate for System A transporters, MeAIB-evoked currents can be recorded from 
hippocampal interneurons.  I hypothesize that enhancing either the KM or VMAX for 
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glutamine transport by SNAT1 following high K+-induced depolarization will increase 
MeAIB-evoked currents.  In addition, I hypothesize that in the absence of 10mM KCl, 
MeAIB should evoke an inward current in immature but not mature slices, providing 
further support for the age-dependent regulation of SNAT1 surface activity.  Although 
this experiment may not be able to distinguish between changes in KM or VMAX ± 10mM 
KCl, one advantage to applying this technique is that biocytin can be injected through the 
recording electrode, allowing post-morphological analysis of the interneuron subtype.  
Further processing of the slice may enable staining for neurochemical markers and thus 
complement future immunohistochemical experiments to elucidate the interneuron 
subtypes that express functional SNAT1.   
 
4) What are the signaling molecules that regulate SNAT1 surface activity? 
To elucidate the signaling molecules that regulate SNAT1 surface activity in 
response to high K+-induced depolarization, I asked if the increase in vesicular GABA 
content and mIPSC amplitude from electrophysiological studies was mediated by an 
increase in synaptic activity (i.e. glutamate) or by an increase in synaptic depolarization 
(i.e. calcium).  If synaptic activity activated a signaling cascade that up-regulates SNAT1 
surface activity, I hypothesized that TTX (0.5µM, added to 10mM KCl ACSF) would 
eliminate the post-stimulation increase in mIPSC amplitudes.  TTX eliminated the 
increase in mIPSC amplitudes at 10 minutes post-stimulation in 3/6 cells (124 ± 14% of 
control, p=0.1, n=6) from immature slices and in 5/7 cells from mature slices (102 ± 3% 
of control, p>0.05, n=7).  Results from this experiment imply that the cellular signals 
regulating SNAT1 surface activity may be developmentally regulated and involve 
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activation by synaptic depolarization in immature slices and by synaptic activity in 
mature slices.  However, the increase in SNAT1-mediated uptake by 10mM KCl 
demonstrated that mechanisms intrinsic to synaptosomes are capable of reproducing the 
depolarization-induced changes observed in hippocampal slices. 
Therefore, to build on these initial experiments, I would first confirm the above 
result by repeating the experiment, especially since the average response in immature 
slices appears skewed by three cells.  Second, if synaptic activity is implicated (at either 
age), I would first explore the role of ionotropic and metabotropic glutamate receptors by 
repeating electrophysiological experiments completed in Chapter III using selective 
pharmacological antagonists ± 10mM KCl.  If synaptic depolarization is implicated, I 
would first explore a role for extracellular calcium by repeating the electrophysiological 
or [3H]MeAIB uptake experiments in ACSF that contains either a low concentration of 
calcium, a calcium chelator, or an inhibitor to voltage-gated calcium channels.  Results 
from these proposed experiments can be confirmed by measuring MeAIB-evoked 
currents in immature and mature slices. 
As noted in Chapter I, SNAT1 possesses three PKC consensus sequences.  Both 
synaptic activity and synaptic depolarization could increase intracellular calcium levels 
and thus activate PKC.  Individual PKC subtypes positively regulate the surface activity 
of EAAT3 in C6 glioma cells, with PKCε enhancing the KM of glutamate for EAAT3 
while PKCα enhances its VMAX through a trafficking-dependent mechanism (Gonzalez et 
al. 2002).  Therefore, a similar phenomenon may occur with SNAT1, allowing individual 
PKC subtypes to enhance glutamine’s KM and VMAX for SNAT1.  Pharmacological 
activators and inhibitors for various PKC subtypes exist, and thus can be applied in 
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electrophysiological, surface biotinylation, and synaptosomal uptake experiments 
±10mM KCl to investigate if PKC is a regulator of SNAT1 surface activity. 
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Age-dependent regulation of SNAT1 surface activity 
 
 Studies in Chapter III support the conclusion that towards the end of the second 
postnatal week, inhibitory terminals reduce the amount of SNAT1 protein expressed and 
the basal uptake activity of SNAT1 to adult levels, which both eliminate glutamine 
supplied by SNAT1 from constitutively contributing to vesicular GABA synthesis.  What 
is the functional role of this age-dependent regulation of SNAT1 surface activity?  As 
noted in Chapter I (Figure 2), functional maturation of the first excitatory synapses 
requires GABA-induced depolarization and thus occurs during P0-P12, prior to reversal 
of the chloride concentration gradient and loss of GABA’s “depolarizing” activity.  In 
order for GABA to serve in this capacity, interneurons must possess metabolic or 
synthetic pathways to maintain synaptic GABA levels during this developmental 
window.  Inhibitory synapses likely encounter little extracellular glutamate supply during 
synapse maturation, yet extracellular glutamine exists at concentrations capable of 
saturating SNAT1.  Therefore, I hypothesize that SNAT1’s constitutive surface activity 
provides interneurons with a mechanism to maintain ongoing GABA synthesis and 
synaptic GABA levels during this developmental window.  This hypothesis is supported 
by the correlation between the postnatal age that chloride’s concentration gradient 
reverses with the postnatal age that SNAT1’s constitutive surface activity is lost (both by 
P14).  By P14, a sufficient density of mature excitatory synapses have formed and thus 
GABA itself functions within a feedback loop to initiate reversal of chloride’s 
concentration gradient and switch its role from an “excitatory” to an inhibitory 
neurotransmitter.  Consequently, this feedback loop may also give rise to a retrograde 
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cellular signal that turns off SNAT1’s constitutive surface activity in an effort to 
transition GABA synthesis from constitutive during P0-P12 to activity-dependent as 
GABA assumes its role as an inhibitory neurotransmitter.   
Elucidating the mechanism that underlies the activity-dependent regulation of 
SNAT1 surface activity will provide insight to the age-dependent regulatory mechanism.  
If synaptic depolarization redistributes SNAT1 to the plasma membrane in mature slices, 
then a cellular signal likely turns off SNAT1’s constitutive surface activity through 
stimulating SNAT1 endocytosis towards the end of the second postnatal week.  In Figure 
19, I demonstrated that developing inhibitory synapses do not down-regulate constitutive 
activity of the entire glu-gln-GABA pathway, indicating that the cellular signal 
selectively targets SNAT1.  To further elucidate the age-dependent regulatory 
mechanism, I propose addressing the questions and experiments below.   
 
1) What is the cellular distribution pattern of SNAT1 protein during postnatal 
development?  
Multiple methodological approaches could be applied to address this question.  As noted 
in the previous section, one approach involves measuring the amount of SNAT1 protein 
expressed in the surface and intracellular fractions in immature and mature hippocampal 
slices using surface biotinylation assays.  In addition, hippocampal synaptosomes could 
be further fractioned into plasma and vesicle membrane fractions and probed for SNAT1 
protein.  If SNAT1’s cellular distribution pattern switches from a surface to 
predominantly an intracellular localization, I hypothesize that SNAT1 will localize to the 
surface and plasma membrane fractions in immature slices and synaptosomes and to the 
142 
intracellular and vesicular membrane fractions in mature slices and synaptosomes, 
respectfully.  These experiments could be completed at multiple postnatal timepoints 
between P12 and P21 in order to narrow the developmental window in which SNAT1 
protein redistribution may occur.  Upon narrowing the developmental window, the 
subcellular distribution pattern of SNAT1 immunoreactivity could be confirmed through 
electron microscopy.  Conversely, if the age-dependent mechanism involves mature 
terminals that express inactive SNAT1 transporters at the cell surface, results from the 
above experiments would provide further support for this mechanism as well. 
 
2) If the mechanism involves SNAT1 endocytosis, does blocking this process retain 
functional SNAT1 protein at the cell surface? 
To address this question, experiments must first identify the mechanism of endocytosis 
and then determine if inhibition of key proteins involved retain SNAT1’s constitutive 
surface activity.  This can be addressed through electrophysiological (± MeAIB during 
resting conditions) and surface activity (basal [3H]MeAIB uptake, surface levels, MeAIB-
evoked currents) measurements in slices or synaptosomes acutely exposed to inhibitors of 
these endocytosis mechanisms.  An alternative approach involves applying the same 
RNAi strategy using in utero electroporation to knockdown expression of these targeted 
proteins and repeating the above experiments. 
 
3) What are the signaling molecules that turn off SNAT1’s constitutive surface activity? 
In addition to GABA, PKC may also function as a cellular signal to turn off SNAT1’s 
constitutive surface activity.  Although PKC increases the surface activity of EAAT3, it 
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also reduces the surface activity of most transporters in the SLC6 gene family, including 
GAT-1 (Melikian 2004).  Therefore, experiments proposed above (#2) could be repeated 
with pharmacological inhibitors to PKC.  Likewise, if the mechanism requires GABA-
induced depolarization to liberate a retrograde signal, experiments that measure SNAT1 
surface activity could be repeated in the presence of GABAA receptor antagonists. 
 
4) Does SNAT1 play a role in synapse maturation during early postnatal development? 
This question can be addressed by examining three primary parameters in wildtype 
hippocampi and hippocampi from P0-P12 rats that express reduced SNAT1 protein 
(RNAi approach using in utero electroporation): GDPs, GABAA and AMPA receptor-
mediated sPSCs, and the neuronal morphology of CA1 pyramidal neurons.  As noted in 
Chapter I, GDPs elicited by activation of GABAA receptors provide the primary source of 
neuronal activity during early postnatal development (P0-P8).  If SNAT1 activity 
contributes to the neurotransmitter pool of GABA that elicits these GDPs, I hypothesize 
that bath application of MeAIB will reduce the amplitude, duration, or frequency of these 
GDPs and spontaneous GABAA receptor-mediated PSCs in wildtype slices.  Similar 
effects should be observed in slices that express a reduced amount of SNAT1 protein.  
Likewise, I hypothesize that reducing SNAT1 protein expression will either eliminate or 
reduce the frequency of AMPA receptor-mediated sPSCs recorded from CA1 pyramidal 
neurons as a consequence of disrupting glutamatergic synapse maturation.  In addition, it 
may disrupt the neuronal morphology of CA1 pyramidal neurons, as GABA-induced 
depolarization contributes to the maturation of cortical pyramidal neuron dendrites.  An 
alternative approach involves repeating the above experiments following daily injections 
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of a SNAT1-selective inhibitor to either the pregnant mothers during late embryonic 
development or to their newly born rat pups.     
 
Because neurons express functional GABA and glutamate receptors at birth, 
GABA serves several trophic roles prior to the formation of synapses, including in the 
proliferation of cortical progenitor cells and in neuronal growth and migration (Wang & 
Kriegstein 2009).  Addition of the GABAA receptor agonist, Muscimol (100µM), 
increases neuronal growth in immature (P0-P7) but not mature (P21+) hippocampal 
neuronal cultures (Marty et al. 1996) due to activation of downstream cellular signals that 
induces transcription of BDNF gene expression (Berninger et al. 1995).  BDNF increases 
SNAT1 uptake activity in cultured neocortical neurons (Burkhalter et al. 2007) and is a 
key player in LTPGABA at immature hippocampal inhibitory synapses (Gubellini et al. 
2005) (see Chapter I).  It would be interesting to determine if BDNF modulates SNAT1 
surface activity to facilitate BDNF and GABA’s role in neuronal growth during early 
postnatal development.  SNAT1 expression in rat hippocampal CA1 area is detected as 
early as E17 (Weiss et al. 2003), but future immunohistochemical studies should examine 
its neuronal localization at both embryonic and postnatal ages.       
In addition, in order for GABA to serve these trophic roles, interneurons must 
possess mechanisms to release GABA prior to the formation of synapses.  In P0 
hippocampal slices, GABAA receptors elicit both spontaneous and evoked “early slow 
currents” that are partially sensitive to inhibitors of voltage-gated channels calcium yet 
insensitive to inhibitors of SNARE-dependent vesicular exocytosis mechanisms 
(Demarque et al. 2002).  Therefore, interneurons likely employ nonvesicular or SNARE-
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independent vesicular exocytosis mechanisms to release GABA during early postnatal 
development.  It would be interesting to determine if bath application of MeAIB reduces 
these GABAA receptor-mediated “early slow currents” in P0 hippocampal slices.  If true, 
it would support that SNAT1 supplies interneurons with glutamine to synthesize GABA 
for nonvesicular release and possibly functions to facilitate GABA’s multiple trophic 
roles during early postnatal development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
Homeostatic regulation of synaptic GABA 
 
 A central conclusion to this thesis research is that modulation of glutamine supply 
by SNAT1’s surface activity dynamically regulates vesicular GABA synthesis and thus 
contributes to the homeostatic regulation of synaptic GABA.  This conclusion further 
supports the existing view that interneurons do not solely rely on GABA reuptake to 
maintain vesicular GABA content.  In Chapter III, I demonstrated that inhibition of GAD 
with 3-MPA reduced mIPSC amplitudes from immature and mature slices (Figure 18), 
indicating that interneurons do not down-regulate the GABA synthetic protein machinery 
along with the constitutive surface activity of SNAT1.  Several intriguing questions 
emerged from this experiment, including: 1) Since SNAT1 is constitutively active in 
immature slices and the extent of mIPSC amplitude reduction by 3-MPA appears greater 
than the effect of MeAIB alone, does both SNAT1 and EAAT3 activity contribute to 
ongoing vesicular GABA synthesis?;  2) Similarly, since SNAT1 is not constitutively 
active during resting conditions in mature hippocampus, is 3-MPA inhibiting GABA 
synthesis from glutamate supplied by EAAT3?;  3) Lastly, why does inhibiting GAD 
activity not completely block synaptic inhibition?   
To address the first two questions, I examined the combined effect of MeAIB 
(10mM) + THA (300µM), a non-selective EAAT substrate that inhibits glutamate 
transport.  If the effect of 3-MPA reflects differing contributions of glutamine and 
glutamate supply to vesicular GABA synthesis, I hypothesized that MeAIB + THA 
should reduce mIPSC amplitudes by a degree comparable to 3-MPA at the respective 
postnatal age.  Unexpectedly, a 5m bath application of MeAIB + THA did not reduce 
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mIPSC amplitudes in either immature (93 ± 7% of control, n=8) or mature (99 ± 9% of 
control, n=3) slices.  A similar result was obtained after a 50m bath application in 
immature slices (data not shown).  One possible explanation for these findings is that a 
compensatory increase in vesicular GABA content by a SNAT1-EAAT3 independent 
mechanism masked an actual reduction in GABA synthesis by MeAIB + THA.  Either 
reuptake of GABA through GAT-1 or GABA synthesis through TCA cycle intermediates 
(glutamate synthesized from α-ketoglutarate) could define this compensatory mechanism.  
Future experiments could evaluate the role of GAT-1 and the TCA cycle as a potential 
compensatory mechanism by repeating the above experiment with the additional presence 
of appropriate pharmacological inhibitors.  As noted in the third question above, 
inhibiting GAD activity does not completely abolish synaptic inhibition.  Two possible 
explanations for this observation are: 1) Under the specified conditions, 3-MPA did not 
completely inhibit GAD activity.  Because 3-MPA inhibits GAD by competing with 
glutamate for the enzyme, the 1h slice incubation in 3-MPA prior to measuring mIPSCs 
likely raised cytosolic glutamate levels and thus could diminish the degree of GAD 
inhibition by 3-MPA.  2) As noted above, a compensatory mechanism that involves 
vesicle filling from reuptake of pre-existing GABA by GAT-1 may prevent complete 
abolishment of synaptic inhibition.   
These findings reveal that homeostatic regulation of synaptic GABA is a complex 
process and is likely governed by several synthetic and metabolic pathways that each 
contribute to vesicular GABA content under specified neuronal conditions.  For example, 
in immature hippocampus, the glu-gln-GABA pathway appears to exist as the preferring 
mechanism to maintain vesicular GABA content during resting conditions, although 
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reuptake of preexisting GABA is expected to also contribute.  GABA synthesized from 
glutamate supplied by EAAT3 may contribute to vesicular GABA content at a 
subpopulation of interneuron terminals (axo-dendritic synapses) and only under neuronal 
conditions that reduce glutamate clearance by EAAT2.  Upon conditions that increase 
neuronal activity in immature hippocampus, both SNAT1 (Chapter III) and EAAT3 
(Mathews & Diamond 2003) contribute to augmenting vesicular GABA content, while 
the contribution by GAT-1 remains unknown.  In mature hippocampus, active GABA 
synthesis appears to occur during resting conditions, yet glutamine supplied by SNAT1 
does not contribute to this process.  For reasons stated above, glutamate supplied by 
EAAT3 likely is not the primary pathway.  In addition to GABA synthesis, reuptake of 
preexisting GABA by GAT-1 does appear to contribute during resting conditions.  
Similar to immature hippocampus, depolarization of mature interneuron terminals allows 
SNAT1 to augment vesicular GABA content and future experiments should investigate a 
possible contribution by GAT-1 and EAAT3.  It will be important for future experiments 
to investigate the proposed contributions above in order to provide a full understanding of 
the mechanisms that maintain homeostatic regulation of synaptic GABA.  In addition, the 
hippocampus expresses varying amounts of GAT-1 and EAAT3 protein throughout 
postnatal development (Figure 16).  Whether these developmental changes occur at 
interneuron terminals to impact the homeostatic regulation of synaptic GABA remains 
unknown and thus should be a focus of future experiments.   
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Role of SNAT1 and GABA in Seizures and Epilepsy 
 
Hippocampus 
Epilepsy is a complex neurological disorder characterized by recurrent seizures 
induced by external (brain trauma, infection, or stroke) or internal (genetic mutations) 
insults.  In temporal lobe epilepsy (TLE), recurrent seizures arise from one or both 
temporal lobes and the hippocampus defines one seizure locus in mesial TLE (mTLE).  
Hippocampal sclerosis defines one pathology of adult mTLE, characterized by atrophy, 
glial proliferation, and preferential loss of neurons in areas CA1, CA3, and the dentate 
hilus.  Impaired energy metabolism due to altered levels of glutamate, glutamine, and 
GABA may partially mediate these pathologies.  Using in vivo microdialysis, the 
hippocampi of medication-resistant epileptic patients contain over a four-fold increase in 
extracellular glutamate levels and slightly reduced glutamine levels compared to 
nonepileptogenic patients (Cavus et al. 2005).  Both a decrease in EAAT2 
immunoreactivity (Proper et al. 2002) and GS activity and protein expression (Eid et al. 
2004) in hippocampus of TLE patients may explain the high and low extracellular 
glutamate and glutamine levels, respectively.   
The slightly reduced glutamine levels in TLE patients may also affect the 
synthesis and extracellular levels of GABA.  A study in patients with complex partial 
epilepsy correlated poor seizure control with low brain GABA levels in brain regions 
outside the hippocampal seizure focus (Petroff et al. 1996).  Immunocytochemical studies 
following in vivo seizure induction reveal reduced GABA-like immunoreactivity in 
synaptic terminals of hippocampal interneurons, suggesting neurotransmitter depletion 
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due to inadequate GABA synthesis (Meldrum et al. 1987).  Consistent with this finding, 
both GAD65 KO mice (Kash et al. 1997) and EAAT3 antisense-treated rats (Sepkuty et 
al. 2002) develop epilepsy, demonstrating that increased demand for GABA must be met 
with increased synthesis.  Two intriguing questions emerge from these studies: 1) Does 
modulation of SNAT1 surface activity provide neuroprotection during periods of 
hyperexcitability? and 2) Conversely, would loss of SNAT1 function lead to 
hyperexcitability and seizure-like activity? 
 Several studies have demonstrated that hyperexcitability and acute ictal-like 
activity (a characteristic of seizures) can be induced in hippocampal slices by elevating 
extracellular potassium (Traynelis & Dingledine 1988, Jensen & Yaari 1997, Dzhala & 
Staley 2003).  In P10-P20 hippocampal-entorhinal cortex slices, elevating the 
extracellular potassium concentration to 8.5mM induced interictal epileptiform 
discharges (IEDs; brief bursts of synchronous population activity) measured by 
extracellular field recordings in area CA3 that spread bi-directionally to area CA1 and the 
dentate hilus region (Dzhala & Staley 2003).  After 2-20 minutes of perfusing high 
potassium, IEDs evolved into ictal-like activity (prolonged epochs of population activity).  
I induced a more moderate level of hyperexcitability by elevating the extracellular 
potassium concentration to 10mM, with the goal of depolarizing neurons, increasing 
synaptic activity and creating a higher demand for synaptic GABA.  High K+-induced 
depolarization increased SNAT1 surface activity and thus vesicular GABA content at 
inhibitory terminals, demonstrating that inhibition is not only maintained, but enhanced 
to counterbalance increased excitatory drive.  Furthermore, it provides evidence that 
SNAT1 may indeed play a neuroprotective role during periods of acute hyperexcitability. 
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 To further elucidate a neuroprotective role for SNAT1, the following questions 
can be addressed in future experiments: 1) During IEDs and ictal-like activity, do 
interneurons upregulate SNAT1 surface activity to maintain or increase vesicular GABA 
content as a compensatory response to maintain or augment synaptic inhibition, 
respectfully?  Given the similarities between mine and Dzhala and Staley’s experimental 
conditions, future experiments can focus on first replicating the induction of IEDs and 
their transition to ictal-like activity in hippocampal-entorhinal cortical slices by elevating 
extracellular potassium.  After recording IEDs and ictal-like activity with an extracellular 
recording electrode, mIPSCs could be recorded from CA1 pyramidal neurons to assess 
changes in vesicular GABA content.  MeAIB-evoked currents could also be recorded 
from area CA1 interneurons to assess changes in SNAT1 surface activity.  In addition, if 
SNAT1 surface activity is indeed increased, it will be important to investigate the 
duration of this upregulation.  This will determine whether interneurons acutely or 
chronically upregulate SNAT1 surface activity in order to meet different metabolic 
demands.  2) What is the cellular mechanism that potentially upregulates SNAT1 surface 
activity following seizure-like activity?  This question can be addressed by first 
investigating the role of cellular signals identified in the activity-dependent regulation of 
SNAT1 surface activity through similar experiments proposed above.   3) Do 
hippocampal slices from rats that overexpress SNAT1 lead to a reduced frequency or 
prolonged onset of IEDs, ictal-like activity, or the transition between the two patterns?  
Conversely, do rats that express a reduced amount of SNAT1 protein develop 
spontaneous seizures?   
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If the above experiments support that modulation of SNAT1 surface activity 
indeed provides a neuroprotective effect during periods of hyperexcitability and seizure-
like activity, it would be interesting to explore SNAT1 function in several transgenic 
mouse models of human epilepsy (upon controlling for differences in species).  The 
majority of these transgenic mouse models are characterized by loss- or gain-of-function 
mutations in voltage- and ligand-gated ion channels that appear to recapitulate several 
types or syndromes of human epilepsy (Bialer & White).  For example, a gain-of-
function mutation in a voltage-gated sodium channel leads to hyperexcitability and 
generalized epilepsy febrile seizures plus (GEFS+; febrile seizures during childhood 
progress to generalized seizures in adults) (Meisler & Kearney 2005).  Likewise, loss-of-
function mutations in distinct voltage-gated sodium, calcium, or potassium channels 
model temporal lobe epilepsy (Bialer & White).  Whether interneurons modulate either 
the age- or activity-dependent regulatory mechanisms that govern SNAT1 surface 
activity in response to chronic periods of hyperexcitability could be explored through 
previously proposed electrophysiological and surface activity measurements in 
hippocampal slices from these transgenic mice.   
 
Thalamus 
 Similar to hippocampal circuitry, dysfunction of thalamocortical circuits allows 
the thalamus to evolve as a seizure locus for specific epilepsy subtypes.  The reticular 
thalamic nucleus encapsulates multiple thalamic nuclei and links the thalamus to the 
cerebral cortex (Pinault 2004).  Thalamic reticular neurons (TRNs) are exclusively 
GABAergic interneurons, and extend their dendrites in multiple planes and in multiple 
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thalamic tiers, while their axons project to several thalamic nuclei.  Thalamocortical and 
corticalthalamic inputs define the primary glutamatergic inputs to TRNs.  Cholinergic, 
GABAergic, and monoaminergic modulatory inputs also innervate TRNs.  These 
morphological features enable some TRNs and TCs to form a reciprocal circuit and 
therefore TRNs provide both feedback and lateral inhibition to TCs (Pinault 2004).  This 
reciprocal circuit generates both sleep-related spindles (6-14Hz) and under certain 
conditions, epileptic oscillations (3Hz synchronized spike-and-wave discharge) 
associated with absence seizures (McCormick & Bal 1997).   
 Studies presented in Chapters II and III focused on SNAT1 function in one sub-
section of one brain region.  However, recent evidence supports that the roles for SNAT1 
in synaptic inhibition may be conserved amongst other brain regions, particularly in the 
reticular thalamic nucleus.  First, thalamic astrocytes appear to exclusively express GAT-
1 independently of postnatal age, indicating that TRNs heavily rely on supply of 
glutamate or glutamine to maintain vesicular GABA synthesis (Vitellaro-Zuccarello et al. 
2003).  Second, preliminary immunohistochemical data from our lab demonstrate that the 
reticular thalamic nucleus highly expresses SNAT1 protein throughout postnatal 
development in rat.  These findings support the hypothesis that astrocytes may supply 
glutamine for neuronal uptake by SNAT1 on TRNs, thereby providing one mechanism to 
maintain vesicular GABA synthesis and inhibitory synaptic transmission in the thalamus. 
A recent study explored the role of glutamine in maintaining both sleep-related 
spindles and epileptic oscillations (induced by antagonizing GABAA receptors) in P11-
P15 horizontal thalamic slices (Bryant et al. 2009).  Maintaining epileptic but not sleep-
related spindle oscillations required glutamine supplied by System A transporters, 
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supporting an activity-dependent role for glutamine in sustaining hyperexcitability of TC 
neurons.  Because induction of epileptiform oscillations required blockade of GABAA 
receptors, this study did not explore the contribution of glutamine to inhibitory 
neurotransmission and thus could be a focus for future experiments.  I hypothesize that 
TRNs may modulate SNAT1 surface activity as a mechanism to maintain or increase 
vesicular GABA content and inhibitory synaptic transmission during these epileptiform 
oscillations.  In addition, because TRN terminals appear to not utilize GABA reuptake by 
GAT-1 as a mechanism to maintain vesicular GABA content, it would also be interesting 
to determine if SNAT1 plays a constitutive role in GABA synthesis.  If true, this would 
support that the primary role for SNAT1 evolved to link the activity-related demands of 
GABA to its rate of synthesis and thus maintain synaptic GABA homeostasis for 
interneurons across multiple brain regions.  
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